MeSH term
Frequency | Condition_Probility | Female | 430 | 0.0 |
Humans | 1225 | 0.0 |
Pregnancy | 36 | 0.0 |
Pregnancy Outcome | 2 | 0.0 |
Randomized Controlled Trials | 2 | 0.0 |
Adult | 242 | 0.0 |
Blood Glucose/metabolism | 2 | 0.0 |
Incidence | 2 | 0.0 |
Male | 441 | 0.0 |
Middle Aged | 277 | 0.0 |
Reference Values | 32 | 0.0 |
Risk Factors | 9 | 0.0 |
Albumins/metabolism | 2 | 1.0 |
Albuminuria/*prevention & control | 2 | 2.0 |
Antihypertensive Agents/*therapeutic use | 2 | 0.0 |
Diabetes Mellitus, Type 2/complications/*drug therapy | 2 | 2.0 |
Hypertension/complications/*drug therapy | 2 | 1.0 |
Indoles/*therapeutic use | 2 | 1.0 |
Renin-Angiotensin System/*drug effects | 2 | 1.0 |
Animals | 525 | 0.0 |
Biological Markers | 14 | 0.0 |
Genes, Tumor Suppressor | 2 | 0.0 |
Oncogenes | 2 | 0.0 |
Alleles | 2 | 0.0 |
Research Support, Non-U.S. Gov't | 758 | 0.0 |
Variation (Genetics) | 9 | 0.0 |
Antigen Presentation | 2 | 0.0 |
B-Lymphocytes/immunology | 2 | 0.0 |
T-Lymphocytes/immunology | 3 | 0.0 |
Breast Neoplasms/*metabolism/pathology | 2 | 1.0 |
Enzyme Inhibitors/*pharmacology | 2 | 0.0 |
Flavonoids/pharmacology | 13 | 3.0 |
Hepatocyte Growth Factor/metabolism | 33 | 63.0 |
Neoplasm Invasiveness/*prevention & control | 3 | 30.0 |
Phosphorylation/drug effects | 16 | 1.0 |
Research Support, U.S. Gov't, P.H.S. | 178 | 0.0 |
Sialoglycoproteins/metabolism | 2 | 4.0 |
Tumor Cells, Cultured | 184 | 1.0 |
Aged | 211 | 0.0 |
Aged, 80 and over | 87 | 0.0 |
Cell Division | 67 | 1.0 |
Hepatocyte Growth Factor/*analysis | 22 | 95.0 |
Prognosis | 53 | 0.0 |
Adolescent | 57 | 0.0 |
DNA Primers/chemistry | 9 | 0.0 |
Gastrins/metabolism | 2 | 10.0 |
Immunoenzyme Techniques | 23 | 0.0 |
Lymph Nodes/pathology | 3 | 1.0 |
Lymphatic Metastasis | 12 | 1.0 |
Preoperative Care | 4 | 2.0 |
Proto-Oncogene Protein c-met/*genetics/metabolism | 4 | 57.0 |
RNA, Messenger/*metabolism | 5 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 71 | 1.0 |
Up-Regulation | 29 | 1.0 |
Angiotensin II/pharmacology | 2 | 2.0 |
Disease Models, Animal | 28 | 1.0 |
Fibroblasts/cytology/drug effects/metabolism | 3 | 5.0 |
Gene Expression Regulation/drug effects | 8 | 0.0 |
Gene Therapy/methods | 5 | 5.0 |
Hamsters | 33 | 0.0 |
Injections, Intramuscular | 9 | 5.0 |
Plasmids/administration & dosage | 2 | 28.0 |
Proto-Oncogene Proteins/genetics/metabolism | 4 | 2.0 |
RNA, Messenger/drug effects/genetics/metabolism | 3 | 3.0 |
Transcription Factors/genetics/metabolism | 2 | 0.0 |
Transforming Growth Factor beta/genetics | 2 | 2.0 |
Growth Substances/*metabolism | 9 | 6.0 |
Hepatocyte Growth Factor/*metabolism | 86 | 82.0 |
Models, Biological | 19 | 0.0 |
Stromal Cells/metabolism | 5 | 5.0 |
Transforming Growth Factor beta/metabolism | 7 | 3.0 |
Cytokines/*physiology | 3 | 1.0 |
Hepatocyte Growth Factor/*cerebrospinal fluid | 2 | 100.0 |
Age Factors | 4 | 0.0 |
Analysis of Variance | 25 | 1.0 |
Cells, Cultured | 248 | 1.0 |
Gene Expression Regulation | 26 | 0.0 |
Polymerase Chain Reaction | 52 | 0.0 |
Proto-Oncogene Protein c-met/physiology | 8 | 100.0 |
RNA, Messenger/analysis | 52 | 1.0 |
Statistics, Nonparametric | 14 | 1.0 |
1-Phosphatidylinositol 3-Kinase/physiology | 5 | 4.0 |
Cattle | 15 | 0.0 |
Cell Line | 124 | 0.0 |
Cell Membrane Permeability | 2 | 1.0 |
Dose-Response Relationship, Drug | 65 | 1.0 |
Hepatocyte Growth Factor/*pharmacology | 136 | 85.0 |
Kinetics | 58 | 0.0 |
Mitogen-Activated Protein Kinases/physiology | 2 | 1.0 |
Protein Kinase C/physiology | 2 | 1.0 |
*Trans-Activators | 3 | 0.0 |
1-Phosphatidylinositol 3-Kinase/antagonists & inhibitors/metabolism | 3 | 3.0 |
Cell Movement/drug effects/physiology | 3 | 5.0 |
Comparative Study | 134 | 0.0 |
Enzyme Inhibitors/pharmacology | 36 | 1.0 |
Fluorescent Antibody Technique | 10 | 0.0 |
Hepatocyte Growth Factor/pharmacology | 39 | 59.0 |
Blood Pressure/drug effects | 2 | 0.0 |
Endothelium, Vascular/physiopathology | 3 | 8.0 |
Hepatocyte Growth Factor/*blood | 98 | 97.0 |
Regression Analysis | 8 | 0.0 |
Chromosome Mapping | 12 | 0.0 |
Karyotyping | 3 | 0.0 |
Ligands | 13 | 0.0 |
Mice | 204 | 0.0 |
Mice, SCID | 12 | 1.0 |
Oncogene Proteins, Fusion/metabolism | 2 | 13.0 |
Proto-Oncogene Protein c-met/*metabolism | 32 | 53.0 |
RNA, Messenger/metabolism | 59 | 1.0 |
Transcription, Genetic | 27 | 0.0 |
Translocation, Genetic | 3 | 0.0 |
Arteriosclerosis Obliterans/therapy | 2 | 100.0 |
Biological Markers/analysis | 11 | 1.0 |
English Abstract | 48 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 88 | 2.0 |
Gene Therapy | 7 | 2.0 |
Liver Regeneration | 21 | 44.0 |
Rats | 192 | 1.0 |
Chronic Disease | 14 | 0.0 |
Gels | 5 | 5.0 |
Hepatocyte Growth Factor/*therapeutic use | 9 | 100.0 |
Leg/blood supply | 3 | 9.0 |
Pilot Projects | 2 | 0.0 |
Wound Healing/*drug effects | 3 | 6.0 |
Interleukin-1/analysis | 2 | 2.0 |
Periodontal Index | 2 | 4.0 |
Statistics | 3 | 0.0 |
Amniotic Fluid/*chemistry | 2 | 4.0 |
Cell Division/drug effects | 120 | 3.0 |
Drug Synergism | 20 | 1.0 |
Epidermal Growth Factor/pharmacology | 26 | 3.0 |
Fibroblast Growth Factors/pharmacology | 2 | 3.0 |
Genistein/pharmacology | 6 | 5.0 |
Growth Inhibitors/pharmacology | 4 | 2.0 |
Growth Substances/*pharmacology | 19 | 5.0 |
Infant, Newborn | 22 | 0.0 |
Insulin-Like Growth Factor I/pharmacology | 11 | 5.0 |
Milk, Human/*chemistry | 2 | 4.0 |
Transforming Growth Factor alpha/pharmacology | 6 | 6.0 |
Tritium/diagnostic use | 2 | 1.0 |
Apoptosis | 19 | 1.0 |
Cell Adhesion | 14 | 1.0 |
Extracellular Matrix/metabolism | 10 | 5.0 |
Genes, p53 | 2 | 0.0 |
Neovascularization, Pathologic | 8 | 2.0 |
Cell Line, Transformed | 7 | 0.0 |
Drug Combinations | 16 | 3.0 |
Endothelial Growth Factors/secretion | 2 | 16.0 |
Lymphokines/secretion | 2 | 5.0 |
Mice, Inbred BALB C | 19 | 0.0 |
*Neovascularization, Pathologic | 9 | 2.0 |
RNA, Neoplasm/biosynthesis | 6 | 4.0 |
Transfection | 78 | 0.0 |
Vascular Endothelial Growth Factor A | 49 | 1.0 |
Vascular Endothelial Growth Factors | 49 | 1.0 |
1-Phosphatidylinositol 3-Kinase/antagonists & inhibitors/*metabolism | 4 | 6.0 |
Apoptosis/*drug effects | 8 | 1.0 |
Calcimycin/pharmacology | 3 | 1.0 |
Cell Survival/drug effects | 12 | 1.0 |
Cytoprotection | 2 | 9.0 |
Epithelium, Corneal/cytology/*drug effects/metabolism | 2 | 40.0 |
Mitogen-Activated Protein Kinase 1/*metabolism | 5 | 4.0 |
Mitogen-Activated Protein Kinase 3 | 15 | 2.0 |
Mitogen-Activated Protein Kinases/*metabolism | 12 | 2.0 |
Proto-Oncogene Proteins/genetics/*metabolism | 5 | 1.0 |
RNA, Small Interfering/metabolism | 2 | 1.0 |
Rabbits | 26 | 0.0 |
Signal Transduction | 53 | 0.0 |
Staurosporine/pharmacology | 3 | 1.0 |
Disease Progression | 32 | 1.0 |
*Gene Expression Regulation, Neoplastic | 9 | 0.0 |
Mice, Nude | 27 | 1.0 |
*Models, Animal | 2 | 6.0 |
Neoplasm Proteins/genetics/metabolism | 2 | 1.0 |
Oligonucleotide Array Sequence Analysis | 3 | 0.0 |
Transplantation, Heterologous | 10 | 1.0 |
Apoptosis/drug effects | 10 | 1.0 |
Blotting, Western/methods | 3 | 1.0 |
Bromodeoxyuridine/metabolism | 4 | 5.0 |
Cell Count/methods | 2 | 3.0 |
Cerebrovascular Circulation/drug effects | 2 | 25.0 |
Microspheres | 6 | 3.0 |
Proto-Oncogene Protein c-met/metabolism | 54 | 72.0 |
Rats, Wistar | 40 | 3.0 |
Recombinant Proteins/administration & dosage | 3 | 3.0 |
Time Factors | 85 | 0.0 |
Blotting, Western | 80 | 1.0 |
Hypoglycemic Agents/pharmacology | 2 | 6.0 |
Interleukin-8/metabolism | 3 | 2.0 |
Transcription Factors/*metabolism | 9 | 0.0 |
Acute Disease | 33 | 1.0 |
Clone Cells | 4 | 0.0 |
Granulocyte Colony-Stimulating Factor/pharmacology | 2 | 1.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/pharmacology | 5 | 1.0 |
Interleukin-3/pharmacology | 7 | 2.0 |
Recombinant Proteins/pharmacology | 77 | 4.0 |
Retrospective Studies | 12 | 0.0 |
Tumor Necrosis Factor-alpha/pharmacology | 18 | 1.0 |
Cell Movement | 30 | 3.0 |
Coronary Vessels | 4 | 14.0 |
Endothelium, Vascular/*drug effects | 2 | 3.0 |
Nitric Oxide/metabolism | 2 | 1.0 |
Signal Transduction/*physiology | 8 | 0.0 |
Genetic Vectors/administration & dosage/genetics | 3 | 12.0 |
Liposomes | 7 | 2.0 |
Rats, Sprague-Dawley | 51 | 2.0 |
Subarachnoid Space | 4 | 44.0 |
Transfection/*methods | 3 | 5.0 |
*Adaptor Proteins, Signal Transducing | 12 | 0.0 |
Cytoskeletal Proteins/metabolism | 9 | 3.0 |
Epithelial Cells/cytology/*metabolism | 2 | 6.0 |
Membrane Proteins/metabolism | 4 | 0.0 |
Mutation | 19 | 0.0 |
Nuclear Proteins/*metabolism | 3 | 0.0 |
Phosphoproteins/metabolism | 7 | 1.0 |
Trans-Activators/metabolism | 7 | 0.0 |
src Homology Domains | 4 | 0.0 |
Biological Markers/*blood | 2 | 1.0 |
Sensitivity and Specificity | 24 | 0.0 |
Fibroblasts/metabolism | 11 | 1.0 |
Immunohistochemistry | 114 | 0.0 |
Neoplasm Invasiveness | 43 | 3.0 |
Stomach Neoplasms/*metabolism/pathology | 2 | 3.0 |
Hepatocyte Growth Factor/*physiology | 48 | 90.0 |
Neoplasm Invasiveness/physiopathology | 2 | 11.0 |
Stromal Cells/drug effects/*metabolism | 2 | 33.0 |
Angiogenesis Inhibitors/*pharmacology | 4 | 4.0 |
Antigens, CD/metabolism | 5 | 0.0 |
Flow Cytometry | 23 | 0.0 |
Leukocytes, Mononuclear/*metabolism | 2 | 1.0 |
Proto-Oncogene Proteins c-bcl-2/*metabolism | 4 | 1.0 |
Thalidomide/*pharmacology | 2 | 11.0 |
Cytokines/metabolism | 4 | 0.0 |
Dimerization | 7 | 0.0 |
Epithelial Cells/pathology | 2 | 2.0 |
Kidney/metabolism | 8 | 2.0 |
Protein Binding | 26 | 0.0 |
Proto-Oncogene Proteins/*metabolism | 9 | 0.0 |
Receptors, Growth Factor/metabolism | 2 | 1.0 |
*Gene Expression Regulation | 9 | 0.0 |
Hepatocyte Growth Factor/chemistry/*genetics | 2 | 100.0 |
*Promoter Regions (Genetics) | 8 | 0.0 |
1-Phosphatidylinositol 3-Kinase/*metabolism | 6 | 2.0 |
Apoptosis/drug effects/physiology | 3 | 3.0 |
Cell Communication/drug effects/physiology | 2 | 20.0 |
Gene Expression Regulation/drug effects/physiology | 3 | 4.0 |
Hepatocyte Growth Factor/*metabolism/pharmacology | 14 | 93.0 |
Integrins/*metabolism | 2 | 1.0 |
Phosphorylation | 81 | 1.0 |
Protein-Serine-Threonine Kinases/*metabolism | 3 | 0.0 |
Signal Transduction/drug effects/physiology | 6 | 2.0 |
Transcription Factors/metabolism | 3 | 0.0 |
Biological Markers/blood | 21 | 1.0 |
Child, Preschool | 25 | 0.0 |
Cohort Studies | 7 | 0.0 |
Endothelial Growth Factors/analysis/*blood | 2 | 25.0 |
Hepatocyte Growth Factor/analysis/*blood | 5 | 100.0 |
Infant | 23 | 0.0 |
Japan | 4 | 0.0 |
Lymphokines/analysis/*blood | 2 | 28.0 |
Predictive Value of Tests | 14 | 0.0 |
Probability | 10 | 1.0 |
Carbon Tetrachloride/toxicity | 2 | 40.0 |
Hepatocyte Growth Factor/genetics/*physiology | 7 | 100.0 |
Hepatocytes/cytology/*drug effects | 3 | 100.0 |
Cell Differentiation | 15 | 0.0 |
Cell Transformation, Neoplastic | 5 | 0.0 |
Epithelial Cells | 25 | 5.0 |
*Neoplasm Invasiveness | 14 | 18.0 |
Proto-Oncogene Protein c-met/*biosynthesis | 14 | 70.0 |
1-Phosphatidylinositol 3-Kinase/metabolism | 16 | 3.0 |
MAP Kinase Kinase 1 | 4 | 2.0 |
Mitogen-Activated Protein Kinase Kinases/metabolism | 2 | 1.0 |
Mitogen-Activated Protein Kinases/metabolism | 25 | 2.0 |
Mitogens/*pharmacology | 8 | 7.0 |
Protein-Serine-Threonine Kinases/metabolism | 6 | 0.0 |
Protein-Tyrosine Kinase/metabolism | 15 | 1.0 |
Signal Transduction/*drug effects | 4 | 1.0 |
Cadherins/biosynthesis | 2 | 7.0 |
Epithelium/pathology | 2 | 1.0 |
Gene Expression | 48 | 0.0 |
Neoplasm Metastasis | 9 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 28 | 0.0 |
Biological Transport | 2 | 0.0 |
Glycosaminoglycans/metabolism | 2 | 4.0 |
Protease Inhibitors/pharmacology | 4 | 1.0 |
Case-Control Studies | 38 | 0.0 |
Cell Movement/drug effects | 43 | 11.0 |
Child | 34 | 0.0 |
Fibroblast Growth Factor 2/pharmacology | 6 | 2.0 |
Plasminogen Activator Inhibitor 1/metabolism | 2 | 4.0 |
Receptors, Cell Surface/metabolism | 6 | 1.0 |
Transforming Growth Factor beta/pharmacology | 14 | 4.0 |
C-Reactive Protein/metabolism | 4 | 1.0 |
Coronary Angiography | 6 | 2.0 |
Hepatocyte Growth Factor/*biosynthesis/blood | 5 | 100.0 |
Inflammation/*metabolism | 3 | 5.0 |
*Drosophila Proteins | 4 | 0.0 |
Pertussis Toxin | 2 | 1.0 |
Virulence Factors, Bordetella/pharmacology | 2 | 1.0 |
Anticoagulants/*therapeutic use | 2 | 4.0 |
Heparin/*therapeutic use | 2 | 8.0 |
Hepatitis, Viral, Human/*blood | 2 | 20.0 |
*Renal Dialysis | 5 | 1.0 |
1-Phosphatidylinositol 3-Kinase/antagonists & inhibitors | 3 | 3.0 |
Chromones/pharmacology | 8 | 3.0 |
Dogs | 33 | 2.0 |
Microscopy, Fluorescence | 11 | 0.0 |
Morpholines/pharmacology | 7 | 2.0 |
COS Cells | 7 | 0.0 |
Carrier Proteins/genetics/*metabolism | 2 | 0.0 |
Down-Regulation/*drug effects | 2 | 3.0 |
Epidermal Growth Factor/*pharmacology | 13 | 1.0 |
Macromolecular Substances | 8 | 0.0 |
Mutation/genetics | 3 | 0.0 |
Protein Binding/drug effects | 3 | 0.0 |
Signal Transduction/drug effects | 7 | 1.0 |
Two-Hybrid System Techniques | 4 | 0.0 |
Ubiquitin/metabolism | 2 | 0.0 |
*Ubiquitin-Protein Ligases | 3 | 0.0 |
Blotting, Northern | 49 | 1.0 |
Cell Line, Tumor | 19 | 0.0 |
Tyrosine/metabolism | 27 | 2.0 |
Kidney Function Tests | 3 | 2.0 |
Risk Assessment | 4 | 0.0 |
Severity of Illness Index | 16 | 1.0 |
Treatment Outcome | 13 | 0.0 |
Tumor Necrosis Factor-alpha/antagonists & inhibitors | 2 | 3.0 |
Reproducibility of Results | 4 | 0.0 |
Blood Proteins/pharmacology | 3 | 6.0 |
Growth Substances/pharmacology | 11 | 5.0 |
Indoles/pharmacology | 3 | 1.0 |
Up-Regulation/drug effects/physiology | 2 | 4.0 |
Enzyme-Linked Immunosorbent Assay/methods | 5 | 1.0 |
Survival Analysis | 18 | 0.0 |
Treatment Failure | 2 | 0.0 |
Neutrophils/*metabolism | 2 | 1.0 |
Biological Markers/analysis/blood | 2 | 6.0 |
Hepatocyte Growth Factor/*analysis/blood | 3 | 100.0 |
Pulmonary Alveoli/chemistry | 2 | 66.0 |
Phenotype | 20 | 0.0 |
Proto-Oncogene Protein c-met/*analysis/genetics | 2 | 100.0 |
Proto-Oncogene Proteins/*analysis/genetics | 2 | 6.0 |
Cell Movement/physiology | 12 | 5.0 |
Epithelial Cells/physiology | 5 | 6.0 |
Gingival Crevicular Fluid/*chemistry | 2 | 20.0 |
Hepatocyte Growth Factor/*analysis/physiology | 3 | 100.0 |
Cell Nucleus/metabolism | 3 | 0.0 |
Culture Media | 14 | 2.0 |
Electrophoresis, Polyacrylamide Gel | 18 | 0.0 |
Fibroblasts/*metabolism | 9 | 5.0 |
Gingiva/cytology/*metabolism | 3 | 30.0 |
Periodontal Ligament/cytology/*metabolism | 2 | 22.0 |
Cyclic AMP/metabolism | 4 | 0.0 |
Hepatocyte Growth Factor/genetics/*metabolism | 18 | 85.0 |
Liver/metabolism | 21 | 2.0 |
Proto-Oncogene Protein c-met/genetics/*metabolism | 11 | 64.0 |
Regeneration/*physiology | 8 | 30.0 |
Gestational Age | 7 | 0.0 |
Hepatocyte Growth Factor/biosynthesis/genetics/*physiology | 4 | 80.0 |
Mesoderm/cytology | 3 | 8.0 |
Morphogenesis | 16 | 7.0 |
Organ Culture Techniques | 6 | 1.0 |
Proto-Oncogene Protein c-met/biosynthesis/genetics/physiology | 2 | 100.0 |
RNA, Messenger/biosynthesis | 30 | 1.0 |
Recombinant Fusion Proteins/pharmacology | 2 | 2.0 |
Myocardial Infarction/blood | 3 | 8.0 |
Diabetic Retinopathy/*metabolism | 2 | 8.0 |
Endothelial Growth Factors/*metabolism | 5 | 1.0 |
Lymphokines/*metabolism | 4 | 0.0 |
Neovascularization, Pathologic/metabolism | 5 | 6.0 |
Biological Assay | 2 | 0.0 |
*Digestive Physiology | 2 | 6.0 |
Hepatocytes | 3 | 25.0 |
Longitudinal Studies | 2 | 0.0 |
Enzyme Activation | 31 | 0.0 |
MAP Kinase Signaling System | 5 | 1.0 |
*Protein-Serine-Threonine Kinases | 17 | 1.0 |
Proto-Oncogene Proteins/metabolism | 21 | 1.0 |
*Mitogens | 10 | 38.0 |
Neovascularization, Pathologic/*prevention & control | 2 | 3.0 |
Microscopy, Confocal | 8 | 0.0 |
Proto-Oncogene Protein c-met/metabolism/*physiology | 2 | 100.0 |
Cell Culture Techniques | 6 | 1.0 |
Culture Media, Conditioned/metabolism | 2 | 6.0 |
Cytokines/pharmacology | 4 | 1.0 |
Interleukin-1/pharmacology | 15 | 2.0 |
RNA, Messenger/genetics | 25 | 0.0 |
Cell Cycle Proteins/genetics/*metabolism | 2 | 1.0 |
Cyclin D1/metabolism | 4 | 2.0 |
Cyclin-Dependent Kinases/metabolism | 2 | 0.0 |
DNA Probes | 8 | 0.0 |
Fibroblast Growth Factors/*pharmacology | 2 | 4.0 |
Gene Expression Profiling | 4 | 0.0 |
Blood Urea Nitrogen | 3 | 5.0 |
Hepatocyte Growth Factor/blood/*pharmacology | 2 | 100.0 |
Injections, Intravenous | 12 | 1.0 |
Kidney/pathology | 3 | 2.0 |
Mercuric Chloride | 2 | 66.0 |
Fluorescent Antibody Technique, Indirect | 4 | 0.0 |
In Situ Nick-End Labeling | 8 | 1.0 |
Neuroprotective Agents/*pharmacology | 2 | 2.0 |
Proto-Oncogene Protein c-met/genetics/metabolism | 8 | 100.0 |
Recombinant Proteins | 21 | 2.0 |
Antibodies/pharmacology | 11 | 3.0 |
Hepatectomy | 14 | 19.0 |
Liver Transplantation | 3 | 5.0 |
Living Donors | 2 | 4.0 |
Postoperative Period | 11 | 3.0 |
DNA/metabolism | 9 | 0.0 |
DNA-Binding Proteins/*metabolism | 10 | 0.0 |
Gene Expression Regulation/physiology | 2 | 0.0 |
Liver/cytology/physiology | 2 | 33.0 |
NF-kappa B/antagonists & inhibitors/*metabolism | 2 | 3.0 |
Transcription, Genetic/drug effects | 8 | 1.0 |
Cell Death/drug effects/physiology | 2 | 4.0 |
Cell Division/physiology | 20 | 2.0 |
Gene Expression/physiology | 6 | 1.0 |
Hepatocyte Growth Factor/*genetics/metabolism | 10 | 100.0 |
Kidney/metabolism/pathology/physiopathology | 2 | 66.0 |
Kidney Failure, Acute/*physiopathology | 2 | 100.0 |
Mice, Inbred Strains | 10 | 1.0 |
Necrosis | 6 | 1.0 |
Culture Media, Serum-Free | 14 | 3.0 |
Epithelial Cells/cytology/drug effects/*metabolism | 2 | 9.0 |
Interferon Type II/*pharmacology | 3 | 0.0 |
Mitogen-Activated Protein Kinase 1/metabolism | 6 | 1.0 |
Amino Acid Sequence | 55 | 0.0 |
CHO Cells | 28 | 1.0 |
Molecular Sequence Data | 99 | 0.0 |
Sequence Homology, Amino Acid | 12 | 0.0 |
Serine Endopeptidases/*metabolism | 7 | 7.0 |
*Trypsin Inhibitor, Kunitz Soybean | 4 | 30.0 |
Lipopolysaccharides/pharmacology | 4 | 0.0 |
Respiration, Artificial | 2 | 3.0 |
Hepatocyte Growth Factor/biosynthesis/*blood | 2 | 100.0 |
Interleukin-6/blood | 7 | 1.0 |
Leukocytes, Mononuclear/metabolism | 3 | 1.0 |
*Autocrine Communication | 4 | 16.0 |
Down-Regulation | 16 | 0.0 |
Precipitin Tests | 21 | 0.0 |
DNA, Complementary/metabolism | 9 | 0.0 |
Proliferating Cell Nuclear Antigen/metabolism | 8 | 3.0 |
Recombinant Proteins/metabolism | 13 | 0.0 |
Regeneration | 5 | 8.0 |
Collagen | 18 | 10.0 |
Laminin | 8 | 8.0 |
Proteoglycans | 9 | 10.0 |
Culture Media, Conditioned/chemistry | 3 | 6.0 |
Endothelium, Vascular/cytology/*drug effects/metabolism | 2 | 2.0 |
Hepatocyte Growth Factor/analysis/*biosynthesis/genetics | 2 | 100.0 |
Interleukin-1/*pharmacology | 7 | 1.0 |
Proto-Oncogene Protein c-met/biosynthesis/genetics | 3 | 60.0 |
Peritoneal Dialysis, Continuous Ambulatory | 2 | 4.0 |
Culture Media, Conditioned/pharmacology | 11 | 6.0 |
Gene Expression/drug effects | 9 | 1.0 |
Platelet-Derived Growth Factor/pharmacology | 2 | 1.0 |
Cell Differentiation/physiology | 4 | 0.0 |
Fibrosis/prevention & control | 2 | 40.0 |
Endothelium, Vascular/cytology/*metabolism | 3 | 1.0 |
Umbilical Veins | 6 | 1.0 |
In Situ Hybridization | 23 | 0.0 |
Base Sequence | 84 | 0.0 |
Endometrium/cytology/*drug effects | 2 | 33.0 |
Epithelial Cells/cytology/*drug effects | 2 | 33.0 |
Hepatocyte Growth Factor/genetics/*pharmacology | 7 | 87.0 |
Proto-Oncogene Protein c-met/genetics | 7 | 38.0 |
RNA, Messenger/genetics/metabolism | 20 | 0.0 |
Sequence Homology, Nucleic Acid | 7 | 0.0 |
Cell Movement/drug effects/*physiology | 2 | 4.0 |
Cell Nucleus/drug effects/physiology | 2 | 28.0 |
Epithelial Cells/cytology/drug effects/physiology | 2 | 25.0 |
Recombinant Fusion Proteins | 2 | 0.0 |
Actins/metabolism | 7 | 1.0 |
Neoplasms/*metabolism | 4 | 4.0 |
Cadherins/*physiology | 4 | 19.0 |
Cell Communication/*drug effects | 2 | 10.0 |
Neoplasm Proteins/metabolism | 4 | 1.0 |
Prostatic Neoplasms/metabolism/*pathology | 4 | 5.0 |
Colitis, Ulcerative/*blood | 2 | 18.0 |
Crohn Disease/*blood | 2 | 10.0 |
Endothelial Growth Factors/blood | 6 | 11.0 |
Fibroblast Growth Factors/blood | 2 | 40.0 |
Lymphokines/blood | 6 | 10.0 |
Hepatocyte Growth Factor/blood | 19 | 86.0 |
Tumor Necrosis Factor-alpha/analysis | 3 | 0.0 |
Capillaries | 3 | 5.0 |
Gene Therapy/*methods | 22 | 5.0 |
Gene Transfer Techniques | 17 | 3.0 |
Hepatocyte Growth Factor/analysis/*genetics | 6 | 100.0 |
Isoproterenol/pharmacology | 2 | 1.0 |
Plasmids | 10 | 0.0 |
Ventricular Remodeling | 3 | 33.0 |
Colonic Neoplasms | 3 | 2.0 |
Gene Expression Regulation, Neoplastic/*drug effects | 2 | 0.0 |
Hepatocyte Growth Factor/*genetics | 33 | 94.0 |
Lipopolysaccharides/*pharmacology | 6 | 1.0 |
Alternative Splicing | 4 | 0.0 |
Interleukin-6/biosynthesis/genetics | 2 | 5.0 |
*Milk Proteins | 2 | 0.0 |
Protein Processing, Post-Translational | 8 | 1.0 |
Signal Transduction/genetics | 2 | 0.0 |
Tumor Cells, Cultured/drug effects/metabolism | 2 | 1.0 |
Gene Dosage | 2 | 0.0 |
Nucleic Acid Hybridization | 8 | 0.0 |
RNA, Messenger/biosynthesis/genetics | 7 | 1.0 |
DNA/genetics | 5 | 0.0 |
DNA Primers | 23 | 0.0 |
Genes, Structural | 3 | 0.0 |
Rats/*genetics | 2 | 3.0 |
Sequence Analysis, DNA | 5 | 0.0 |
Species Specificity | 2 | 0.0 |
Endothelium, Vascular/cytology/drug effects/metabolism | 3 | 7.0 |
*Gene Therapy/methods | 3 | 18.0 |
Glucose/pharmacology | 2 | 1.0 |
Interstitial Collagenase/metabolism | 2 | 8.0 |
Neovascularization, Physiologic/*drug effects | 6 | 6.0 |
Sendai virus/genetics | 3 | 42.0 |
Cell Count | 8 | 0.0 |
Chick Embryo | 8 | 1.0 |
Endothelium, Vascular/cytology/*drug effects | 5 | 6.0 |
Hepatocyte Growth Factor/*chemistry | 2 | 100.0 |
Neovascularization, Physiologic/*drug effects/physiology | 2 | 11.0 |
Protein Structure, Secondary | 3 | 0.0 |
Protein Structure, Tertiary | 15 | 0.0 |
Osmolar Concentration | 8 | 1.0 |
Cadaver | 2 | 0.0 |
Tissue Distribution | 17 | 0.0 |
Coronary Circulation | 2 | 8.0 |
Antineoplastic Agents/therapeutic use | 3 | 1.0 |
Combined Modality Therapy | 14 | 1.0 |
Hepatocyte Growth Factor/*antagonists & inhibitors | 3 | 100.0 |
Microcirculation | 2 | 0.0 |
Mitogens | 2 | 2.0 |
Promoter Regions (Genetics) | 18 | 0.0 |
Trans-Activation (Genetics) | 5 | 0.0 |
Trans-Activators/*physiology | 2 | 0.0 |
Transcription, Genetic/physiology | 3 | 1.0 |
Transforming Growth Factor beta/*physiology | 4 | 3.0 |
Antineoplastic Agents/*pharmacology | 7 | 0.0 |
Hepatocyte Growth Factor/metabolism/*pharmacology | 6 | 85.0 |
Neovascularization, Pathologic/drug therapy | 3 | 10.0 |
Xenograft Model Antitumor Assays | 6 | 2.0 |
Insects | 2 | 1.0 |
Dinoprostone/biosynthesis | 2 | 3.0 |
Hepatocyte Growth Factor/metabolism/*physiology | 4 | 80.0 |
Isoenzymes/*metabolism | 3 | 1.0 |
Prostaglandin-Endoperoxide Synthase/*metabolism | 2 | 3.0 |
Neurons/metabolism | 2 | 0.0 |
Collagen/genetics | 2 | 2.0 |
DNA/*administration & dosage | 3 | 33.0 |
Fibrosis | 9 | 6.0 |
Models, Animal | 2 | 0.0 |
Ascitic Fluid/metabolism | 4 | 21.0 |
Blood Physiology | 2 | 2.0 |
Cell Division/drug effects/physiology | 12 | 4.0 |
Collagen/biosynthesis | 2 | 4.0 |
Keratin/metabolism | 3 | 2.0 |
Vimentin/metabolism | 3 | 2.0 |
Arthritis, Rheumatoid/*blood | 2 | 4.0 |
Cell Cycle | 4 | 0.0 |
Cercopithecus aethiops | 3 | 0.0 |
S Phase | 2 | 0.0 |
Cloning, Molecular | 26 | 0.0 |
DNA, Complementary | 5 | 0.0 |
Culture Techniques | 4 | 0.0 |
Microscopy, Electron | 5 | 0.0 |
Trophoblasts/cytology/*physiology | 2 | 11.0 |
Cytokines/blood | 4 | 1.0 |
Endothelial Growth Factors/*blood | 6 | 2.0 |
Fibroblast Growth Factor 2/*blood | 4 | 7.0 |
Lymphokines/*blood | 6 | 2.0 |
Platelet Count | 3 | 0.0 |
Transforming Growth Factor beta/*blood | 4 | 15.0 |
Protein Subunits | 2 | 0.0 |
Rats, Inbred Lew | 6 | 2.0 |
Caco-2 Cells | 5 | 1.0 |
Cadherins/metabolism | 6 | 4.0 |
Carrier Proteins/metabolism | 3 | 0.0 |
Cell Differentiation/*drug effects | 3 | 1.0 |
Immunoblotting | 10 | 0.0 |
Microfilament Proteins/metabolism | 2 | 2.0 |
Prospective Studies | 21 | 0.0 |
Cell Survival | 7 | 0.0 |
DNA Replication | 5 | 1.0 |
Hepatocyte Growth Factor/biosynthesis/*genetics | 3 | 60.0 |
Recombinant Fusion Proteins/biosynthesis | 4 | 0.0 |
Thymidine/metabolism | 11 | 3.0 |
Helicobacter pylori/*physiology | 2 | 13.0 |
Neovascularization, Physiologic | 9 | 5.0 |
Carcinoma, Hepatocellular/*pathology | 6 | 12.0 |
Cell Division/*physiology | 4 | 2.0 |
Liver Neoplasms/*pathology | 6 | 10.0 |
Mitogen-Activated Protein Kinases/antagonists & inhibitors/*metabolism | 3 | 3.0 |
Blotting, Southern | 9 | 0.0 |
Dactinomycin/pharmacology | 3 | 0.0 |
Gerbillinae | 2 | 5.0 |
Immunohistochemistry/methods | 5 | 0.0 |
Respirovirus/genetics | 3 | 42.0 |
Aspartate Aminotransferases/blood | 5 | 3.0 |
*Bone Marrow Transplantation | 4 | 1.0 |
C-Reactive Protein/analysis | 5 | 0.0 |
Transplantation, Homologous | 6 | 0.0 |
Hepatocyte Growth Factor/*analysis/genetics | 3 | 100.0 |
Serine Endopeptidases/*analysis/genetics | 2 | 66.0 |
Protein Kinase C/antagonists & inhibitors/*metabolism | 2 | 2.0 |
Signal Transduction/physiology | 21 | 2.0 |
Stress, Mechanical | 2 | 0.0 |
Hepatocyte Growth Factor/*biosynthesis/blood/genetics | 3 | 100.0 |
Hepatocyte Growth Factor/blood/*metabolism | 9 | 100.0 |
Lung/metabolism | 6 | 3.0 |
Spleen/metabolism | 7 | 5.0 |
Tumor Markers, Biological | 4 | 0.0 |
*MAP Kinase Kinase Kinase 1 | 3 | 2.0 |
MAP Kinase Signaling System/drug effects/*physiology | 2 | 5.0 |
Hepatocyte Growth Factor/analysis | 4 | 80.0 |
Fibroblast Growth Factors/metabolism | 2 | 3.0 |
Insulin-Like Growth Factor I/metabolism | 3 | 1.0 |
*Mucins | 2 | 2.0 |
*Muscle Proteins | 3 | 1.0 |
*Neuropeptides | 2 | 1.0 |
Peptides/metabolism | 2 | 0.0 |
Transforming Growth Factor alpha/metabolism | 2 | 2.0 |
Hepatocyte Growth Factor/*immunology | 3 | 100.0 |
Intercellular Adhesion Molecule-1/metabolism | 2 | 1.0 |
Lymphocyte Culture Test, Mixed | 3 | 0.0 |
Monocytes/*immunology/metabolism | 2 | 5.0 |
*Proto-Oncogene Proteins | 19 | 1.0 |
*Receptors, Growth Factor | 8 | 24.0 |
Cytokines/physiology | 2 | 1.0 |
Growth Substances/physiology | 3 | 2.0 |
Binding Sites | 21 | 0.0 |
Collagen/metabolism | 5 | 1.0 |
Crystallography, X-Ray | 2 | 0.0 |
Models, Molecular | 5 | 0.0 |
Protein Conformation | 6 | 0.0 |
Infusions, Intravenous | 5 | 0.0 |
Sequence Deletion | 8 | 0.0 |
Injections, Intraventricular | 2 | 1.0 |
Proto-Oncogene Proteins c-bcl-2/metabolism | 6 | 1.0 |
Rats, Inbred Strains | 4 | 0.0 |
Aqueous Humor/*metabolism | 2 | 9.0 |
Cell Movement/*drug effects | 13 | 13.0 |
*Apoptosis | 11 | 0.0 |
Mice, Knockout | 4 | 0.0 |
Transforming Growth Factor beta/*pharmacology | 11 | 2.0 |
Hepatocyte Growth Factor/genetics/pharmacology | 2 | 100.0 |
Mice, Inbred C57BL | 26 | 0.0 |
Mice, Transgenic | 15 | 0.0 |
Surface Properties | 2 | 1.0 |
Endothelial Growth Factors/physiology | 4 | 6.0 |
Hindlimb/blood supply | 4 | 16.0 |
Ischemia/*therapy | 2 | 10.0 |
Lymphokines/physiology | 4 | 4.0 |
Hepatocyte Growth Factor/*genetics/physiology | 7 | 100.0 |
Interleukin-6/*therapeutic use | 2 | 33.0 |
Hepatocyte Growth Factor/analysis/*biosynthesis | 4 | 100.0 |
Proto-Oncogene Proteins/analysis/*biosynthesis | 2 | 8.0 |
Hela Cells | 3 | 0.0 |
Placenta/metabolism | 4 | 2.0 |
*Neoplasm Metastasis | 3 | 3.0 |
Protein Kinase C/*metabolism | 4 | 1.0 |
Cell Death/drug effects | 4 | 2.0 |
Enzyme Activation/drug effects | 12 | 1.0 |
Hydrogen Peroxide/pharmacology | 2 | 0.0 |
Proteins/*metabolism | 3 | 0.0 |
Sequence Alignment | 7 | 0.0 |
Hepatocyte Growth Factor/*biosynthesis/genetics | 11 | 91.0 |
Neoplasm Staging | 12 | 0.0 |
Proto-Oncogene Protein c-met/*biosynthesis/genetics | 5 | 83.0 |
Hematopoiesis, Extramedullary/*physiology | 2 | 25.0 |
Hepatocyte Growth Factor/genetics/metabolism/*therapeutic use | 2 | 100.0 |
*Transfection | 3 | 1.0 |
Cell Separation | 7 | 0.0 |
*Genetic Vectors | 6 | 1.0 |
Green Fluorescent Proteins | 5 | 0.0 |
Liver/cytology | 8 | 12.0 |
Plasmids/metabolism | 5 | 0.0 |
RNA/metabolism | 4 | 0.0 |
Recombinant Fusion Proteins/metabolism | 2 | 0.0 |
*Transcription, Genetic | 3 | 0.0 |
Kidney/*physiology | 3 | 7.0 |
Gastric Mucosa/*metabolism/pathology | 3 | 23.0 |
Hepatocyte Growth Factor/genetics/metabolism/*physiology | 2 | 100.0 |
Carcinoma, Papillary/metabolism | 2 | 18.0 |
Thyroid Gland/metabolism | 3 | 5.0 |
Thyroid Neoplasms/*genetics | 2 | 2.0 |
Cell Division/drug effects/genetics | 2 | 2.0 |
Genes, Dominant | 2 | 0.0 |
Survival Rate | 18 | 0.0 |
Tumor Stem Cell Assay | 4 | 2.0 |
Adenocarcinoma/*metabolism/pathology | 3 | 2.0 |
Lung Neoplasms/*metabolism/pathology | 4 | 5.0 |
Neoplasm Transplantation | 16 | 1.0 |
DNA Primers/genetics | 4 | 0.0 |
Gene Expression Regulation, Developmental | 5 | 0.0 |
Growth Substances/genetics/*pharmacology | 4 | 80.0 |
Receptor Protein-Tyrosine Kinases/genetics | 4 | 2.0 |
Receptors, Cell Surface/genetics | 2 | 1.0 |
Cell Communication/physiology | 3 | 3.0 |
Linear Models | 2 | 0.0 |
*Gene Transfer Techniques | 7 | 1.0 |
Hepatocyte Growth Factor/*biosynthesis/*genetics | 2 | 100.0 |
Retroviridae/genetics | 9 | 2.0 |
Transduction, Genetic | 3 | 0.0 |
Carcinoma, Papillary/*metabolism/pathology | 5 | 27.0 |
Thyroid Neoplasms/*metabolism/pathology | 6 | 13.0 |
Trans-Activators/*metabolism | 5 | 0.0 |
Tumor Markers, Biological/*metabolism | 2 | 0.0 |
DNA, Neoplasm/analysis | 2 | 0.0 |
Ki-67 Antigen/analysis | 2 | 0.0 |
B-Lymphocytes/*immunology | 2 | 0.0 |
Fibroblasts/immunology | 2 | 2.0 |
Growth Substances/*biosynthesis | 7 | 15.0 |
Muscle, Smooth, Vascular/drug effects/metabolism | 2 | 14.0 |
Wound Healing/drug effects | 2 | 6.0 |
United States | 3 | 0.0 |
Prevalence | 2 | 0.0 |
Myocardium/metabolism | 4 | 1.0 |
Active Transport, Cell Nucleus | 2 | 0.0 |
Enzyme Induction/drug effects | 4 | 1.0 |
Oxidation-Reduction | 2 | 0.0 |
Sirolimus/pharmacology | 2 | 2.0 |
Actins/physiology | 2 | 5.0 |
Growth Substances/*physiology | 8 | 5.0 |
Mesoderm/physiology | 2 | 5.0 |
Morphogenesis/physiology | 4 | 12.0 |
*Nerve Growth Factors | 2 | 1.0 |
Growth Substances/*blood | 3 | 11.0 |
Cadherins/*biosynthesis | 2 | 6.0 |
Coculture Techniques | 20 | 2.0 |
Umbilical Veins/cytology | 7 | 2.0 |
Embolization, Therapeutic | 3 | 17.0 |
Liver/*physiology | 2 | 4.0 |
Liver Regeneration/*physiology | 6 | 24.0 |
Adenocarcinoma/metabolism/pathology | 3 | 5.0 |
Autocrine Communication/physiology | 3 | 11.0 |
Lasers | 2 | 1.0 |
Follow-Up Studies | 9 | 0.0 |
Radioimmunoassay | 6 | 0.0 |
Endostatins | 2 | 4.0 |
Fibroblast Growth Factor 2/blood | 8 | 24.0 |
Neovascularization, Pathologic/*blood | 3 | 27.0 |
Ribonuclease, Pancreatic/blood | 2 | 40.0 |
Tumor Markers, Biological/*blood | 8 | 1.0 |
Cell Adhesion/drug effects | 5 | 1.0 |
Cycloheximide/pharmacology | 5 | 0.0 |
Integrins/*physiology | 2 | 2.0 |
Kidney | 7 | 1.0 |
Tetradecanoylphorbol Acetate/pharmacology | 15 | 0.0 |
Enzyme Activation/physiology | 2 | 1.0 |
Blood Pressure | 3 | 0.0 |
Creatinine/blood | 7 | 2.0 |
Serum Albumin/metabolism | 2 | 1.0 |
Protein-Tyrosine Kinase/*metabolism | 9 | 1.0 |
Hepatocyte Growth Factor/chemistry/genetics/*metabolism | 2 | 100.0 |
Activins | 3 | 4.0 |
DNA, Recombinant | 2 | 1.0 |
Gene Expression Regulation, Neoplastic/drug effects | 3 | 0.0 |
Inhibins/pharmacology | 2 | 11.0 |
Insulin/*biosynthesis | 2 | 22.0 |
Islets of Langerhans/metabolism | 2 | 5.0 |
Luminescent Proteins/genetics/metabolism | 2 | 1.0 |
Recombinant Fusion Proteins/genetics/metabolism | 3 | 0.0 |
Transcription Factors/*genetics | 2 | 0.0 |
Adaptation, Physiological | 2 | 2.0 |
Nephrectomy | 5 | 5.0 |
Swine | 6 | 0.0 |
*Transplantation, Heterologous | 3 | 4.0 |
Cytokines/*biosynthesis | 2 | 0.0 |
Epithelial Cells/*metabolism | 2 | 1.0 |
Receptors, Growth Factor/biosynthesis | 2 | 7.0 |
Drug Evaluation, Preclinical | 2 | 1.0 |
Macaca fascicularis | 2 | 0.0 |
Receptor, Epidermal Growth Factor/metabolism | 2 | 0.0 |
Stomach Neoplasms/*pathology | 6 | 12.0 |
Mice, Inbred ICR | 2 | 0.0 |
Hepatocyte Growth Factor/*antagonists & inhibitors/*pharmacology | 2 | 100.0 |
Pancreatic Neoplasms/*pathology | 3 | 8.0 |
DNA, Complementary/genetics | 8 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction/veterinary | 2 | 7.0 |
*Tumor Markers, Biological | 2 | 1.0 |
Paraffin Embedding | 2 | 0.0 |
Culture Media, Conditioned | 20 | 5.0 |
Endothelial Growth Factors/pharmacology | 3 | 2.0 |
Epithelial Cells/drug effects/physiology | 2 | 16.0 |
Lymphokines/pharmacology | 3 | 1.0 |
Microscopy, Electron, Scanning | 2 | 0.0 |
Cell Culture Techniques/methods | 4 | 1.0 |
Fibroblasts/physiology | 5 | 4.0 |
Cell Polarity/drug effects | 2 | 28.0 |
Androstadienes/pharmacology | 5 | 1.0 |
Endothelium, Vascular/*drug effects/metabolism | 2 | 3.0 |
Protein-Serine-Threonine Kinases/antagonists & inhibitors/*metabolism | 2 | 2.0 |
Carcinoma, Hepatocellular/metabolism | 2 | 2.0 |
Liver/*metabolism/pathology | 3 | 10.0 |
Liver Neoplasms/metabolism | 3 | 4.0 |
*Cell Communication | 2 | 2.0 |
Fibroblast Growth Factor 2/physiology | 3 | 12.0 |
Menopause | 2 | 0.0 |
Stem Cell Factor/physiology | 2 | 15.0 |
Serine Endopeptidases/metabolism | 2 | 1.0 |
p38 Mitogen-Activated Protein Kinases | 8 | 1.0 |
Antibodies, Monoclonal | 5 | 0.0 |
Nitrobenzenes/pharmacology | 2 | 8.0 |
Sulfonamides/pharmacology | 3 | 2.0 |
Dose-Response Relationship, Immunologic | 3 | 0.0 |
Interleukin-6/*physiology | 2 | 2.0 |
RNA, Messenger/antagonists & inhibitors/biosynthesis | 2 | 8.0 |
Cations | 3 | 3.0 |
Delayed-Action Preparations | 2 | 1.0 |
Gelatin | 2 | 13.0 |
Injections, Subcutaneous | 3 | 0.0 |
Mitogens/*genetics | 3 | 42.0 |
Electrophoresis, Agar Gel | 3 | 0.0 |
*Variation (Genetics) | 2 | 0.0 |
Gene Expression Regulation, Neoplastic | 14 | 0.0 |
Antineoplastic Agents/pharmacology | 2 | 0.0 |
Neovascularization, Pathologic/blood | 2 | 15.0 |
Epithelial Cells/drug effects | 3 | 9.0 |
Ovarian Neoplasms/*metabolism/pathology | 2 | 3.0 |
Tumor Cells, Cultured/drug effects | 9 | 1.0 |
Serine Endopeptidases/genetics/*metabolism | 2 | 9.0 |
Endothelium, Vascular/cytology/*drug effects/physiology | 2 | 10.0 |
*Kringles | 2 | 40.0 |
Biopsy | 7 | 0.0 |
Neoplasm Proteins/*biosynthesis/blood/genetics | 2 | 66.0 |
*Proto-Oncogenes | 7 | 1.0 |
Fibroblasts/cytology/drug effects/*metabolism | 2 | 13.0 |
Image Processing, Computer-Assisted | 2 | 0.0 |
Nuclear Proteins/*physiology | 2 | 1.0 |
Protein Precursors/metabolism | 2 | 1.0 |
3T3 Cells | 9 | 0.0 |
Antineoplastic Agents/*toxicity | 2 | 3.0 |
Receptor, Epidermal Growth Factor/*metabolism | 4 | 0.0 |
Endothelium, Vascular/cytology/drug effects | 2 | 3.0 |
Growth Inhibitors/*pharmacology | 3 | 1.0 |
Hepatocyte Growth Factor/*blood/genetics | 3 | 100.0 |
Liver/*embryology/metabolism | 2 | 66.0 |
Pregnancy Trimester, Second | 3 | 1.0 |
Ribonucleases/metabolism | 2 | 1.0 |
Oligonucleotides, Antisense/pharmacology | 3 | 1.0 |
Androgens/*physiology | 2 | 4.0 |
Drug Resistance, Neoplasm | 2 | 0.0 |
Hepatocyte Growth Factor/antagonists & inhibitors/genetics/*metabolism | 2 | 100.0 |
*Paracrine Communication | 2 | 12.0 |
Prostatic Neoplasms/genetics/*metabolism/pathology | 2 | 8.0 |
RNA Interference | 2 | 0.0 |
DNA/analysis | 3 | 0.0 |
Coronary Vessels/cytology | 2 | 14.0 |
Lipoproteins, LDL/*pharmacology | 2 | 3.0 |
*Avian Proteins | 2 | 2.0 |
Gene Deletion | 3 | 0.0 |
Phosphotyrosine/metabolism | 7 | 1.0 |
Hepatocyte Growth Factor/*pharmacology/physiology | 5 | 83.0 |
In Vitro | 36 | 0.0 |
Receptor, Macrophage Colony-Stimulating Factor/metabolism | 2 | 25.0 |
Imidazoles/pharmacology | 4 | 1.0 |
Isoenzymes/metabolism | 7 | 1.0 |
Lung Neoplasms | 2 | 1.0 |
Mitosis/drug effects | 4 | 3.0 |
Pyridines/pharmacology | 3 | 1.0 |
Biopsy, Needle | 3 | 0.0 |
Bone Neoplasms | 2 | 9.0 |
Multiple Myeloma/*pathology | 2 | 3.0 |
Metalloendopeptidases/metabolism | 2 | 3.0 |
Chickens | 3 | 0.0 |
Enzyme-Linked Immunosorbent Assay/*methods | 2 | 1.0 |
Antigens, CD95/*physiology | 2 | 2.0 |
Proto-Oncogene Proteins/*physiology | 6 | 2.0 |
*Tumor Suppressor Proteins | 2 | 0.0 |
Fibroblasts/drug effects/*metabolism | 2 | 4.0 |
Skin/cytology | 4 | 2.0 |
Anticoagulants/administration & dosage/*pharmacology | 2 | 22.0 |
Endothelial Growth Factors/metabolism | 3 | 1.0 |
Heparin/administration & dosage/*pharmacology | 2 | 15.0 |
Lymphokines/metabolism | 4 | 1.0 |
Hepatocyte Growth Factor/biosynthesis | 8 | 88.0 |
Proliferating Cell Nuclear Antigen/analysis | 4 | 1.0 |
Stomach Neoplasms/*metabolism | 3 | 6.0 |
Catalysis | 2 | 0.0 |
Cell Movement/*physiology | 9 | 4.0 |
Hepatocyte Growth Factor/*biosynthesis | 29 | 90.0 |
Interleukin-1/metabolism | 2 | 0.0 |
Gastrointestinal Diseases/*blood | 2 | 40.0 |
Renal Dialysis | 3 | 0.0 |
Angioplasty, Transluminal, Percutaneous Coronary | 2 | 4.0 |
Creatine Kinase/blood | 7 | 6.0 |
Electrocardiography | 2 | 0.0 |
Recurrence | 10 | 0.0 |
*Gene Expression | 10 | 0.0 |
Proto-Oncogene Protein c-met/analysis/*genetics | 3 | 75.0 |
*Receptors, Cell Surface | 3 | 0.0 |
Animals, Newborn | 2 | 0.0 |
RNA, Messenger | 3 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction/methods | 2 | 0.0 |
Carcinoma, Hepatocellular/*enzymology | 2 | 8.0 |
Gene Library | 9 | 0.0 |
Protein Isoforms | 3 | 0.0 |
*Signal Transduction | 10 | 0.0 |
Disease-Free Survival | 3 | 0.0 |
*Gene Therapy | 8 | 2.0 |
Genetic Vectors | 14 | 0.0 |
Hepatocyte Growth Factor/genetics/metabolism | 2 | 66.0 |
Antineoplastic Combined Chemotherapy Protocols/therapeutic use | 3 | 0.0 |
Growth Substances/metabolism | 7 | 5.0 |
Gelatinase A/metabolism | 3 | 5.0 |
Laminin/metabolism | 3 | 2.0 |
Liver/pathology | 9 | 4.0 |
Organ Size | 3 | 1.0 |
Proteoglycans/metabolism | 4 | 5.0 |
Urinary Plasminogen Activator/biosynthesis | 3 | 30.0 |
MAP Kinase Signaling System/drug effects | 3 | 3.0 |
Proto-Oncogene Protein c-met/biosynthesis | 6 | 85.0 |
Kidney Failure, Chronic/physiopathology/therapy | 2 | 20.0 |
Transforming Growth Factor beta/physiology | 7 | 7.0 |
Antigens, Nuclear | 2 | 1.0 |
Nuclear Proteins/metabolism | 5 | 0.0 |
Urinary Plasminogen Activator/*biosynthesis/genetics | 2 | 25.0 |
Antigens, CD95/metabolism | 3 | 2.0 |
Cytokines/*pharmacology | 6 | 1.0 |
Bronchoalveolar Lavage Fluid/*chemistry | 5 | 8.0 |
*Fibroblast Growth Factors | 12 | 13.0 |
Cell Survival/physiology | 5 | 2.0 |
Heart Catheterization | 2 | 3.0 |
Hepatocyte Growth Factor/blood/*secretion | 2 | 100.0 |
Myocardium/*metabolism | 2 | 0.0 |
Hepatocyte Growth Factor/administration & dosage/*pharmacology | 2 | 100.0 |
Ischemia/pathology/*physiopathology | 2 | 50.0 |
Portal Vein | 5 | 23.0 |
Recombinant Proteins/administration & dosage/pharmacology | 3 | 5.0 |
Hepatocyte Growth Factor/analysis/*pharmacology | 3 | 100.0 |
Pre-Eclampsia/*metabolism | 2 | 9.0 |
Angiotensin II/*antagonists & inhibitors | 2 | 7.0 |
Angiotensin-Converting Enzyme Inhibitors/pharmacology | 2 | 2.0 |
Fibroblasts/cytology | 4 | 1.0 |
Receptors, Angiotensin/antagonists & inhibitors | 3 | 6.0 |
Tetrazoles/pharmacology | 2 | 5.0 |
Carcinoma, Signet Ring Cell/genetics/*metabolism/pathology | 2 | 100.0 |
Cell Cycle/drug effects | 4 | 0.0 |
Hepatocyte Growth Factor/*analysis/biosynthesis | 2 | 100.0 |
Breast Neoplasms/*pathology | 3 | 1.0 |
Diagnosis, Differential | 4 | 0.0 |
Interleukin-6/*blood | 2 | 0.0 |
Bromodeoxyuridine/pharmacology | 2 | 3.0 |
Epithelial Cells/cytology | 2 | 2.0 |
Fibroblast Growth Factor 2/metabolism | 6 | 6.0 |
Gelatinases/metabolism | 2 | 6.0 |
Wound Healing | 9 | 7.0 |
Proto-Oncogene Protein c-met/analysis | 3 | 37.0 |
Epithelial Cells/*physiology | 2 | 6.0 |
Protein-Tyrosine Kinase/genetics/metabolism | 2 | 2.0 |
Mitogen-Activated Protein Kinases/antagonists & inhibitors/metabolism | 2 | 2.0 |
Molecular Weight | 16 | 0.0 |
DNA/biosynthesis | 41 | 7.0 |
Liver Function Tests | 10 | 5.0 |
Chemotaxis, Leukocyte | 2 | 1.0 |
Proto-Oncogene Protein c-met/genetics/*physiology | 3 | 75.0 |
8-Bromo Cyclic Adenosine Monophosphate/pharmacology | 2 | 2.0 |
Skin Physiology | 3 | 8.0 |
Chloramphenicol O-Acetyltransferase/genetics | 3 | 1.0 |
Gene Expression Regulation, Enzymologic/physiology | 2 | 2.0 |
Transcription Factors/*physiology | 2 | 0.0 |
Cats | 2 | 0.0 |
Isoenzymes | 2 | 1.0 |
Inflammation | 3 | 0.0 |
Autoradiography | 7 | 1.0 |
Anti-Inflammatory Agents, Non-Steroidal/*pharmacology | 2 | 1.0 |
Fibroblasts/*physiology | 6 | 10.0 |
*Helicobacter pylori | 2 | 1.0 |
Hepatocyte Growth Factor/*biosynthesis/pharmacology | 3 | 100.0 |
Hepatocyte Growth Factor/pharmacology/*physiology | 4 | 66.0 |
Mastectomy | 2 | 2.0 |
Temperature | 2 | 0.0 |
Tumor Markers, Biological/*analysis | 4 | 0.0 |
Gene Therapy/adverse effects/*methods | 2 | 28.0 |
Hepatocyte Growth Factor/*administration & dosage/adverse effects/blood | 2 | 100.0 |
Leg Ulcer/diagnosis/therapy | 2 | 100.0 |
Magnetic Resonance Angiography | 2 | 12.0 |
Pain Measurement | 2 | 2.0 |
Peripheral Vascular Diseases/diagnosis/*therapy | 2 | 100.0 |
Regional Blood Flow | 2 | 1.0 |
Thromboangiitis Obliterans/classification/therapy | 2 | 100.0 |
Apolipoproteins/genetics/*metabolism | 2 | 20.0 |
Apolipoproteins B/genetics/metabolism | 2 | 28.0 |
Hepatoblastoma/*metabolism/pathology | 2 | 40.0 |
Liver Neoplasms/metabolism/pathology | 2 | 12.0 |
Complement 5a/pharmacology | 2 | 8.0 |
Interleukin-8/pharmacology | 3 | 6.0 |
N-Formylmethionine Leucyl-Phenylalanine/pharmacology | 2 | 0.0 |
alpha 1-Antitrypsin/metabolism | 2 | 4.0 |
Cell Adhesion Molecules/metabolism | 3 | 1.0 |
Enzyme Induction | 4 | 0.0 |
Naphthalenes/pharmacology | 2 | 2.0 |
Phospholipase C/metabolism | 2 | 0.0 |
Acetic Acid | 2 | 11.0 |
Membrane Glycoproteins/*metabolism | 3 | 0.0 |
Liver/*metabolism | 11 | 2.0 |
Restriction Mapping | 5 | 0.0 |
Serine Endopeptidases/*genetics | 2 | 3.0 |
Cytoskeletal Proteins/*metabolism | 2 | 1.0 |
Hepatocyte Growth Factor/physiology | 6 | 54.0 |
Body Fluids/metabolism | 3 | 10.0 |
Immunologic Techniques | 2 | 0.0 |
Receptor Protein-Tyrosine Kinases/metabolism | 18 | 7.0 |
Receptors, Vascular Endothelial Growth Factor | 2 | 0.0 |
Retinal Detachment/metabolism | 2 | 100.0 |
Diabetic Nephropathies/*metabolism/*pathology | 2 | 100.0 |
Extracellular Matrix Proteins/metabolism | 3 | 3.0 |
Kidney/*pathology | 3 | 5.0 |
In Situ Hybridization, Fluorescence | 2 | 0.0 |
Fibroblasts/drug effects/metabolism | 9 | 6.0 |
Indomethacin/pharmacology | 3 | 1.0 |
Fibrosis/metabolism | 2 | 16.0 |
Monocyte Chemoattractant Protein-1/metabolism | 3 | 4.0 |
RANTES/metabolism | 2 | 3.0 |
Transforming Growth Factor beta/*metabolism | 6 | 2.0 |
Myocardial Infarction/*blood | 4 | 6.0 |
Liver/cytology/*metabolism | 6 | 8.0 |
Proto-Oncogene Protein c-met/*physiology | 5 | 45.0 |
L-Lactate Dehydrogenase/blood | 3 | 2.0 |
Recombinant Proteins/therapeutic use | 9 | 2.0 |
Chemotaxis/*drug effects | 5 | 10.0 |
RNA, Neoplasm/analysis | 3 | 1.0 |
Receptor Protein-Tyrosine Kinases/*biosynthesis | 9 | 16.0 |
Receptors, Cell Surface/*biosynthesis | 3 | 5.0 |
*Neovascularization, Physiologic | 7 | 3.0 |
Cryopreservation | 4 | 3.0 |
RNA, Messenger/genetics/*metabolism | 2 | 1.0 |
*Receptors, Fibroblast Growth Factor | 2 | 15.0 |
Receptors, Growth Factor/genetics/metabolism | 2 | 9.0 |
Transforming Growth Factor alpha/genetics/metabolism | 2 | 16.0 |
Transcription Factors/physiology | 2 | 0.0 |
Transfection/genetics | 2 | 1.0 |
Proto-Oncogene Protein c-met/*genetics | 6 | 50.0 |
Cell Membrane/metabolism | 8 | 0.0 |
Epithelial Cells/metabolism | 7 | 2.0 |
Hepatocyte Growth Factor/genetics/*metabolism/pharmacology | 3 | 100.0 |
Ovarian Neoplasms/*metabolism | 2 | 3.0 |
Proto-Oncogene Protein c-met/*analysis | 6 | 66.0 |
Kidney Tubules/*metabolism/ultrastructure | 2 | 100.0 |
Cell Polarity | 4 | 3.0 |
Cell Size | 4 | 1.0 |
Mitogen-Activated Protein Kinase Kinases/physiology | 2 | 8.0 |
Antibodies, Monoclonal/pharmacology | 2 | 0.0 |
Stimulation, Chemical | 9 | 1.0 |
Bleomycin | 2 | 25.0 |
*Disease Models, Animal | 2 | 0.0 |
Hydroxyproline/analysis | 3 | 27.0 |
Specific Pathogen-Free Organisms | 2 | 2.0 |
*Liver Regeneration | 14 | 40.0 |
Liver Transplantation/*physiology | 3 | 15.0 |
Epidermal Growth Factor/physiology | 3 | 3.0 |
Growth Substances/genetics/*physiology | 2 | 11.0 |
Platelet-Derived Growth Factor/physiology | 2 | 5.0 |
Wound Healing/*physiology | 2 | 3.0 |
Autopsy | 2 | 1.0 |
Alanine Transaminase/blood | 8 | 4.0 |
Cytokines/*blood | 2 | 0.0 |
Transforming Growth Factor beta/blood | 4 | 15.0 |
Tumor Necrosis Factor-alpha/metabolism | 3 | 0.0 |
Cell Culture Techniques/*methods | 2 | 2.0 |
Fetus/cytology | 2 | 3.0 |
Gene Expression Regulation, Enzymologic | 3 | 0.0 |
Hepatocyte Growth Factor/analysis/blood | 2 | 100.0 |
Multivariate Analysis | 5 | 0.0 |
Hepatocyte Growth Factor/*chemistry/genetics/*metabolism | 2 | 100.0 |
Mutagenesis | 5 | 0.0 |
*Cell Cycle | 2 | 0.0 |
Colony-Stimulating Factors/*administration & dosage/metabolism | 2 | 100.0 |
*Hematopoietic Stem Cell Mobilization | 4 | 6.0 |
Leukemia, Myeloid/metabolism/*pathology/*therapy | 2 | 100.0 |
Receptors, Colony-Stimulating Factor/metabolism | 3 | 33.0 |
Lung Neoplasms/metabolism/pathology/*surgery | 2 | 100.0 |
Pleura/*metabolism | 2 | 100.0 |
Interleukin-11/*secretion | 2 | 100.0 |
Multiple Myeloma/*complications/metabolism/pathology | 2 | 100.0 |
Osteoblasts/*metabolism/pathology | 2 | 66.0 |
Osteolysis/etiology/*metabolism/pathology | 2 | 100.0 |
Fibroblasts/drug effects | 2 | 2.0 |
Gingiva/cytology/*drug effects | 3 | 75.0 |
RNA/analysis | 5 | 2.0 |
Trophoblasts/*physiology | 3 | 16.0 |
Biocompatible Materials | 2 | 3.0 |
DNA/*biosynthesis | 5 | 5.0 |
Extracellular Matrix/*metabolism | 2 | 2.0 |
Heparan Sulfate Proteoglycan/metabolism | 2 | 7.0 |
Pregnancy Trimester, Third | 2 | 1.0 |
beta 2-Microglobulin/blood | 2 | 8.0 |
Cell Communication/*physiology | 3 | 4.0 |
Prostatic Neoplasms/*pathology | 3 | 2.0 |
Stromal Cells/physiology | 3 | 5.0 |
Tumor Cells, Cultured/pathology | 2 | 3.0 |
Chemotaxis | 5 | 2.0 |
Ovarian Cysts/*metabolism | 2 | 50.0 |
Ovary/metabolism | 3 | 3.0 |
Carcinoma, Hepatocellular | 4 | 1.0 |
Liver Neoplasms | 5 | 1.0 |
Receptors, LDL/*genetics | 4 | 2.0 |
Cell Division/*drug effects | 6 | 2.0 |
Insulin-Like Growth Factor I/*metabolism | 3 | 2.0 |
Kidney Tubules/*metabolism | 3 | 18.0 |
Chemotaxis/drug effects | 3 | 3.0 |
Lung/injuries | 2 | 66.0 |
Proto-Oncogene Protein c-met/*genetics/*metabolism | 2 | 100.0 |
Proto-Oncogenes/drug effects | 2 | 22.0 |
Up-Regulation/drug effects | 3 | 0.0 |
Heparin/*pharmacology | 6 | 4.0 |
Cell Count/drug effects | 2 | 2.0 |
Amino Acid Substitution | 2 | 0.0 |
Proto-Oncogenes | 13 | 7.0 |
Recombinant Fusion Proteins/physiology | 3 | 1.0 |
Cell Size/drug effects | 2 | 2.0 |
Nitric Oxide/*metabolism | 3 | 2.0 |
Nitric-Oxide Synthase/antagonists & inhibitors/genetics/metabolism | 2 | 50.0 |
Trophoblasts/cytology/*drug effects/metabolism | 2 | 66.0 |
Fibroblasts/cytology/physiology | 3 | 3.0 |
Hepatocyte Growth Factor/biosynthesis/*physiology | 6 | 100.0 |
*Chromosomes, Human, Pair 7 | 9 | 3.0 |
*Embolization, Therapeutic | 2 | 8.0 |
Neoplasm Proteins/*analysis | 2 | 0.0 |
Fibroblasts/cytology/metabolism | 3 | 1.0 |
Hepatocyte Growth Factor/biosynthesis/*pharmacology | 4 | 100.0 |
Pancreatic Neoplasms/*metabolism/pathology | 2 | 4.0 |
Receptor, Epidermal Growth Factor/biosynthesis | 2 | 4.0 |
Aspartate Aminotransferases/metabolism | 2 | 11.0 |
Bilirubin/metabolism | 2 | 10.0 |
Leukocyte Count | 3 | 0.0 |
Lung | 11 | 12.0 |
Trans-Activation (Genetics)/*drug effects | 2 | 2.0 |
Endometriosis/*metabolism/pathology | 3 | 18.0 |
Aorta | 5 | 3.0 |
Apoptosis/drug effects/*physiology | 2 | 0.0 |
Adenocarcinoma/metabolism/*pathology | 3 | 5.0 |
*Hepatectomy | 11 | 30.0 |
Postoperative Complications/*blood | 2 | 9.0 |
Follicular Fluid/*metabolism | 2 | 7.0 |
Hepatocyte Growth Factor/*genetics/*metabolism | 2 | 100.0 |
Epithelial Cells/cytology/drug effects | 2 | 8.0 |
Interferon Type II/pharmacology | 3 | 0.0 |
Gingiva/cytology/immunology/*metabolism | 2 | 66.0 |
Gelatinase B | 2 | 2.0 |
*JNK Mitogen-Activated Protein Kinases | 2 | 2.0 |
Mitogen-Activated Protein Kinase 1 | 3 | 2.0 |
*Mitogen-Activated Protein Kinases | 2 | 0.0 |
Hepatocyte Growth Factor/*genetics/metabolism/physiology | 2 | 100.0 |
Caspases/metabolism | 4 | 0.0 |
Endotoxins/toxicity | 2 | 11.0 |
Lipopolysaccharides/*toxicity | 2 | 3.0 |
Hepatocyte Growth Factor/*physiology/therapeutic use | 3 | 100.0 |
Hypertrophy | 5 | 4.0 |
Ligation | 2 | 2.0 |
Liver/metabolism/*pathology | 3 | 15.0 |
Rats, Inbred F344 | 13 | 3.0 |
Liver/drug effects/*metabolism | 3 | 4.0 |
Carbohydrate Sequence | 2 | 0.0 |
Molecular Structure | 4 | 0.0 |
Endothelium, Vascular/cytology/metabolism | 2 | 1.0 |
Cell Proliferation | 3 | 1.0 |
Phosphoproteins/*metabolism | 2 | 0.0 |
src-Family Kinases/metabolism | 2 | 1.0 |
Epithelial Cells/cytology/metabolism | 3 | 5.0 |
Mesoderm/metabolism | 2 | 2.0 |
Mice, Inbred C3H | 3 | 0.0 |
Cell Adhesion/physiology | 2 | 0.0 |
Carcinogens/pharmacology | 3 | 3.0 |
Gene Amplification | 2 | 0.0 |
Hepatocyte Growth Factor/biosynthesis/genetics | 4 | 57.0 |
DNA, Complementary/analysis | 2 | 0.0 |
*Chemoembolization, Therapeutic | 2 | 8.0 |
Graft Survival | 2 | 0.0 |
Endometrial Neoplasms/*pathology | 2 | 18.0 |
Proto-Oncogene Protein c-met/biosynthesis/*physiology | 2 | 100.0 |
*Liver Transplantation | 4 | 2.0 |
Adenoviridae/*genetics | 3 | 1.0 |
Bromodeoxyuridine | 3 | 9.0 |
Cytomegalovirus/genetics | 2 | 2.0 |
Liver/cytology/metabolism | 3 | 6.0 |
Cell Communication | 6 | 2.0 |
Homeostasis | 2 | 0.0 |
Antibody Specificity | 6 | 0.0 |
Proto-Oncogene Protein c-met/*biosynthesis/immunology | 2 | 100.0 |
Antineoplastic Agents, Phytogenic/pharmacology | 2 | 2.0 |
Etoposide/pharmacology | 2 | 1.0 |
Stem Cell Factor/pharmacology | 2 | 1.0 |
Hematopoiesis | 4 | 1.0 |
Tumor Markers, Biological/blood | 5 | 3.0 |
Receptors, Cell Surface/*analysis | 3 | 2.0 |
Recombinant Proteins/chemistry/metabolism | 3 | 0.0 |
1-(5-Isoquinolinesulfonyl)-2-methylpiperazine/pharmacology | 2 | 6.0 |
Stromal Cells/*metabolism | 3 | 8.0 |
Hematopoietic Stem Cells | 2 | 3.0 |
Liver Diseases/physiopathology | 2 | 33.0 |
Liver Regeneration/physiology | 5 | 50.0 |
Membrane Glycoproteins/metabolism | 2 | 0.0 |
Genotype | 3 | 0.0 |
Mice, Inbred DBA | 2 | 0.0 |
Liver/cytology/drug effects/*metabolism | 6 | 30.0 |
Cell Differentiation/drug effects | 14 | 1.0 |
Genes, Reporter | 3 | 0.0 |
Endometrium/cytology/metabolism | 2 | 33.0 |
Hepatocyte Growth Factor/*biosynthesis/physiology | 3 | 100.0 |
Liver/chemistry | 4 | 4.0 |
Hepatocyte Growth Factor/*secretion | 4 | 100.0 |
Interleukin-6/*secretion | 2 | 5.0 |
Body Weight/drug effects | 3 | 1.0 |
Mitotic Index/drug effects | 2 | 15.0 |
Rats, Inbred SHR | 2 | 2.0 |
Weight Loss/drug effects | 2 | 10.0 |
Liver Circulation | 4 | 23.0 |
Densitometry | 2 | 1.0 |
Interleukin-6/biosynthesis | 2 | 0.0 |
T-Lymphocytes/*physiology | 2 | 0.0 |
Blood Cell Count | 4 | 1.0 |
Multiple Myeloma/*metabolism/pathology | 2 | 10.0 |
Cell Transformation, Viral | 2 | 0.0 |
Mutagenesis, Insertional | 3 | 1.0 |
*Hepatocyte Growth Factor | 2 | 18.0 |
Structure-Activity Relationship | 12 | 0.0 |
Receptor Protein-Tyrosine Kinases/genetics/*physiology | 2 | 7.0 |
Receptors, Cell Surface/genetics/*physiology | 2 | 3.0 |
Hematopoietic Cell Growth Factors/*therapeutic use | 3 | 50.0 |
*Hematopoietic Stem Cell Transplantation | 10 | 2.0 |
Adenocarcinoma/*pathology | 3 | 3.0 |
Endometrium/*cytology/drug effects | 2 | 100.0 |
Calcium/blood | 3 | 1.0 |
Transforming Growth Factor beta/biosynthesis | 3 | 6.0 |
Hepatocyte Growth Factor/blood/genetics/*metabolism | 2 | 100.0 |
Receptor Protein-Tyrosine Kinases/*immunology | 2 | 11.0 |
Receptor, Epidermal Growth Factor/analysis | 4 | 2.0 |
Carcinoma, Hepatocellular/complications/pathology/*surgery | 2 | 66.0 |
Hormones/*pharmacology | 2 | 4.0 |
Cells, Cultured/metabolism | 2 | 5.0 |
Laser-Doppler Flowmetry | 3 | 7.0 |
Muscle, Smooth, Vascular/cytology | 2 | 6.0 |
Neovascularization, Physiologic/*genetics | 2 | 5.0 |
Dyes/pharmacology | 2 | 2.0 |
Neoplasms/*metabolism/pathology | 2 | 6.0 |
Polymers/chemistry | 2 | 8.0 |
Tissue Engineering/*methods | 2 | 11.0 |
Hepatocyte Growth Factor/genetics | 3 | 60.0 |
Transforming Growth Factor beta/*genetics/metabolism | 2 | 11.0 |
Cell Division/genetics | 4 | 1.0 |
Retroviridae/*genetics | 3 | 2.0 |
Cell Adhesion/drug effects/physiology | 2 | 3.0 |
Endothelium, Vascular/cytology | 5 | 2.0 |
Hepatocyte Growth Factor/blood/*physiology | 3 | 100.0 |
Protein-Tyrosine Kinase/*physiology | 3 | 2.0 |
*Hematopoiesis | 4 | 2.0 |
Transplantation, Autologous | 6 | 1.0 |
ADP-ribosyl Cyclase | 2 | 0.0 |
*Antigens, CD | 2 | 0.0 |
Antigens, CD34/*blood | 2 | 2.0 |
Colony-Forming Units Assay | 5 | 0.0 |
Hematopoietic Cell Growth Factors/therapeutic use | 2 | 40.0 |
Hepatocyte Growth Factor/*chemistry/metabolism | 3 | 100.0 |
Kringles | 6 | 40.0 |
Breast Neoplasms/*blood/pathology | 2 | 18.0 |
Embryonic and Fetal Development/physiology | 4 | 4.0 |
Hydrogen-Ion Concentration | 3 | 0.0 |
Angina Pectoris/*blood | 2 | 9.0 |
Artifacts | 2 | 3.0 |
Cell-Free System | 3 | 1.0 |
Copper/*chemistry | 2 | 18.0 |
Edetic Acid/pharmacology | 2 | 1.0 |
Histidine/chemistry | 2 | 4.0 |
Inhibitory Concentration 50 | 2 | 0.0 |
Thyroid Gland/*metabolism | 2 | 4.0 |
Thyroid Neoplasms/metabolism | 2 | 10.0 |
RNA, Messenger/*biosynthesis | 5 | 2.0 |
Trophoblasts/metabolism | 3 | 8.0 |
Chromatography, Affinity | 6 | 0.0 |
Heparin/metabolism | 5 | 4.0 |
Epithelium/physiology | 4 | 4.0 |
Dexamethasone/pharmacology | 9 | 1.0 |
Receptor Protein-Tyrosine Kinases/*analysis | 7 | 14.0 |
Antineoplastic Agents/adverse effects/therapeutic use | 2 | 25.0 |
Proto-Oncogene Proteins/genetics | 2 | 0.0 |
Endothelium, Vascular/drug effects/*metabolism | 2 | 2.0 |
Rats, Inbred WKY | 3 | 4.0 |
Vasoconstrictor Agents/pharmacology | 2 | 5.0 |
Antineoplastic Agents/*administration & dosage | 2 | 3.0 |
Culture Media, Serum-Free/pharmacology | 2 | 1.0 |
Signal Transduction/drug effects/*physiology | 2 | 0.0 |
Liver Regeneration/*drug effects | 4 | 44.0 |
*CDC2-CDC28 Kinases | 2 | 0.0 |
Ca(2+)-Calmodulin Dependent Protein Kinase/metabolism | 3 | 0.0 |
Hepatoblastoma | 2 | 11.0 |
Interleukin-6/physiology | 2 | 3.0 |
Hepatocyte Growth Factor/*blood/metabolism | 3 | 100.0 |
Fibronectins/metabolism | 2 | 1.0 |
Luciferases/metabolism | 3 | 0.0 |
Protein Transport | 2 | 0.0 |
Cross-Linking Reagents | 3 | 0.0 |
Nutritional Status | 2 | 1.0 |
Asialoglycoprotein Receptor | 2 | 8.0 |
Receptors, Cell Surface/*metabolism | 8 | 1.0 |
Receptors, Growth Factor/genetics/*metabolism | 2 | 6.0 |
Carcinoma, Non-Small-Cell Lung/*metabolism/pathology | 2 | 8.0 |
Carcinoma, Squamous Cell/metabolism/pathology | 2 | 5.0 |
Serum Albumin/biosynthesis | 2 | 14.0 |
Ca(2+)-Calmodulin Dependent Protein Kinase/*metabolism | 2 | 0.0 |
Binding Sites/genetics | 3 | 0.0 |
Proto-Oncogenes/*genetics | 3 | 4.0 |
Gene Expression Regulation, Developmental/*physiology | 2 | 1.0 |
Pancreatic Neoplasms/*metabolism | 3 | 4.0 |
Calcium/metabolism | 3 | 0.0 |
Cell Differentiation/genetics | 3 | 1.0 |
Genes, ras | 3 | 1.0 |
Cell Differentiation/drug effects/physiology | 2 | 2.0 |
Collagen/pharmacology | 2 | 1.0 |
Laminin/pharmacology | 2 | 4.0 |
Neoplasm Invasiveness/pathology | 2 | 3.0 |
Azepines/pharmacology | 2 | 9.0 |
Intestines/metabolism | 2 | 1.0 |
Platelet Activating Factor/*pharmacology | 2 | 8.0 |
*Receptors, G-Protein-Coupled | 2 | 0.0 |
Triazoles/pharmacology | 2 | 6.0 |
Liver/*pathology | 2 | 3.0 |
Tumor Necrosis Factor-alpha/*pharmacology | 2 | 0.0 |
Fibroblasts/*drug effects/metabolism | 3 | 6.0 |
Teichoic Acids/*pharmacology | 2 | 8.0 |
Pulmonary Fibrosis/blood/*metabolism | 2 | 100.0 |
Endothelium, Vascular/*cytology/drug effects | 2 | 4.0 |
Heparin/pharmacology | 5 | 2.0 |
Cell Aging | 2 | 2.0 |
Quinones/pharmacology | 2 | 1.0 |
Skin/*cytology | 2 | 4.0 |
Stem Cell Factor/biosynthesis | 2 | 50.0 |
ROC Curve | 2 | 1.0 |
Breast Neoplasms/*blood/mortality/pathology | 2 | 33.0 |
Insulin-Like Growth Factor I/physiology | 2 | 6.0 |
Regeneration/drug effects/physiology | 2 | 66.0 |
Membranes, Artificial | 2 | 2.0 |
Alprostadil/pharmacology | 3 | 11.0 |
Cholera Toxin/pharmacology | 2 | 2.0 |
Dinoprostone/pharmacology | 5 | 6.0 |
Fibroblasts | 6 | 1.0 |
Gastric Mucosa/*drug effects | 2 | 50.0 |
Prostaglandin-Endoperoxide Synthase/metabolism | 4 | 5.0 |
Prostaglandins/*pharmacology | 2 | 8.0 |
Hepatocyte Growth Factor/biosynthesis/*pharmacology/*physiology | 2 | 100.0 |
Liver/cytology/*drug effects/metabolism | 2 | 12.0 |
Recombinant Proteins/pharmacology/therapeutic use | 2 | 5.0 |
Gene Frequency | 2 | 0.0 |
Hepatocyte Growth Factor/biosynthesis/genetics/pharmacology | 2 | 100.0 |
Endopeptidases/metabolism | 2 | 1.0 |
Down-Regulation/drug effects | 2 | 0.0 |
Anti-Ulcer Agents/*pharmacology | 2 | 9.0 |
Mitogens/pharmacology | 2 | 0.0 |
Tissue Extracts/*pharmacology | 2 | 8.0 |
Glycoproteins/*physiology | 2 | 3.0 |
Mutagenesis, Site-Directed | 6 | 0.0 |
*Oncogenes | 2 | 0.0 |
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use | 2 | 0.0 |
CA-19-9 Antigen/blood | 2 | 8.0 |
Carcinoembryonic Antigen/blood | 2 | 3.0 |
Vascular Endothelial Growth Factor A/blood | 4 | 9.0 |
Epithelium/metabolism | 8 | 2.0 |
Recombinant Proteins/chemistry | 3 | 0.0 |
Binding, Competitive | 3 | 0.0 |
Kidney/cytology | 2 | 1.0 |
Kidney Neoplasms | 2 | 11.0 |
Nitriles/pharmacology | 2 | 1.0 |
Bronchoalveolar Lavage Fluid/chemistry | 3 | 4.0 |
Evaluation Studies | 4 | 0.0 |
Dimethylnitrosamine | 2 | 100.0 |
Organ Size/drug effects | 4 | 4.0 |
Gastric Mucosa/cytology/drug effects/*physiology | 2 | 66.0 |
Growth Substances/*biosynthesis/genetics | 3 | 11.0 |
Interleukin-4/pharmacology | 2 | 0.0 |
Protein Biosynthesis | 6 | 0.0 |
Adenocarcinoma/*metabolism | 2 | 2.0 |
Hepatocyte Growth Factor/administration & dosage/blood/*pharmacokinetics | 2 | 100.0 |
Recombinant Proteins/administration & dosage/blood/pharmacokinetics | 2 | 50.0 |
Aorta/metabolism | 2 | 5.0 |
Imidazoles/*pharmacology | 2 | 2.0 |
Organ Specificity | 10 | 0.0 |
Dinoprostone/metabolism | 2 | 2.0 |
Mice, Transgenic/genetics | 2 | 3.0 |
Staining and Labeling | 3 | 0.0 |
Bilirubin/blood | 4 | 4.0 |
Ovary/*cytology | 2 | 25.0 |
Circular Dichroism | 2 | 0.0 |
Nuclear Proteins/analysis | 2 | 1.0 |
Proto-Oncogene Protein c-met | 111 | 83.0 |
Hepatocyte Growth Factor/*antagonists & inhibitors/*genetics | 2 | 100.0 |
Endothelium, Vascular/cytology/drug effects/*physiology | 2 | 4.0 |
Phosphodiesterase Inhibitors/pharmacology | 2 | 1.0 |
*Chromosome Mapping | 3 | 0.0 |
Receptor Protein-Tyrosine Kinases/*genetics/metabolism | 6 | 9.0 |
Hydrolysis | 2 | 0.0 |
Scattering, Radiation | 3 | 2.0 |
Placenta/*metabolism | 3 | 1.0 |
DNA/biosynthesis/drug effects | 2 | 7.0 |
Cell Transplantation | 2 | 2.0 |
Cornea/metabolism | 2 | 13.0 |
Serum Albumin/analysis | 2 | 1.0 |
Carcinoma, Hepatocellular/*metabolism | 3 | 2.0 |
Interleukin-6/pharmacology | 4 | 1.0 |
Receptors, Cell Surface/*genetics/metabolism | 2 | 2.0 |
DNA, Neoplasm/biosynthesis | 4 | 3.0 |
Receptor Protein-Tyrosine Kinases/analysis/*biosynthesis | 2 | 28.0 |
Conserved Sequence | 3 | 0.0 |
Recombinant Proteins/genetics/metabolism | 2 | 0.0 |
Receptor Protein-Tyrosine Kinases/biosynthesis | 5 | 16.0 |
Embryo/physiology | 2 | 5.0 |
Epithelium/drug effects | 5 | 12.0 |
CCAAT-Enhancer-Binding Proteins | 2 | 1.0 |
NF-kappa B/metabolism | 2 | 0.0 |
Cytological Techniques | 2 | 5.0 |
Epithelium/metabolism/pathology | 3 | 4.0 |
Receptor Protein-Tyrosine Kinases/genetics/*metabolism | 5 | 4.0 |
1-Phosphatidylinositol 3-Kinase | 2 | 1.0 |
*Cell Transformation, Neoplastic | 3 | 0.0 |
Receptor Protein-Tyrosine Kinases/*metabolism | 8 | 3.0 |
Embryonic and Fetal Development | 5 | 1.0 |
Transforming Growth Factor alpha/*blood | 2 | 66.0 |
Antigens, CD34 | 4 | 0.0 |
Cytokines/*metabolism | 2 | 0.0 |
Receptor Protein-Tyrosine Kinases/*genetics | 4 | 1.0 |
Factor XIIa/antagonists & inhibitors | 2 | 100.0 |
Clinical Trials | 4 | 0.0 |
Granulocyte Colony-Stimulating Factor/*therapeutic use | 4 | 6.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/*therapeutic use | 5 | 19.0 |
Bone Marrow/*metabolism | 2 | 4.0 |
Bone Marrow Cells | 4 | 0.0 |
*Chromosome Deletion | 2 | 0.0 |
Hematopoietic Cell Growth Factors/*pharmacology | 4 | 8.0 |
Radiotherapy/adverse effects | 2 | 5.0 |
Vincristine/administration & dosage/adverse effects | 2 | 18.0 |
Carcinoma, Hepatocellular/*metabolism/pathology | 3 | 4.0 |
Liver Neoplasms/*metabolism/pathology | 4 | 5.0 |
Neoplasm Proteins/*metabolism | 4 | 0.0 |
Tumor Cells, Cultured/metabolism | 2 | 1.0 |
DNA Replication/drug effects | 9 | 5.0 |
Iodine Radioisotopes | 4 | 1.0 |
Hematopoietic Stem Cells/metabolism | 2 | 1.0 |
*Cell Differentiation | 2 | 0.0 |
RNA-Directed DNA Polymerase | 2 | 1.0 |
Stromal Cells/*physiology | 2 | 8.0 |
Neoplasm Recurrence, Local/blood | 2 | 12.0 |
Cytokines/analysis | 2 | 2.0 |
Albumins/genetics | 3 | 13.0 |
RNA, Messenger/*analysis | 6 | 1.0 |
Endothelium, Vascular/*cytology/drug effects/*physiology | 2 | 18.0 |
Glyceraldehyde-3-Phosphate Dehydrogenases/metabolism | 2 | 9.0 |
Receptors, Platelet-Derived Growth Factor/metabolism | 2 | 4.0 |
Receptor Protein-Tyrosine Kinases/*biosynthesis/genetics | 3 | 8.0 |
Bucladesine/pharmacology | 3 | 1.0 |
Epithelium/drug effects/metabolism | 2 | 3.0 |
Hepatocyte Growth Factor/*biosynthesis/*pharmacology | 3 | 100.0 |
Interleukin-6/metabolism | 3 | 1.0 |
Recombinant Proteins/biosynthesis/metabolism | 2 | 1.0 |
HL-60 Cells | 2 | 0.0 |
Mink | 4 | 6.0 |
Transforming Growth Factor beta/antagonists & inhibitors | 2 | 12.0 |
Hematopoiesis/*physiology | 3 | 3.0 |
Growth Substances/isolation & purification/*physiology | 2 | 50.0 |
Glycoproteins/metabolism | 2 | 1.0 |
Proteins/metabolism | 2 | 0.0 |
Tissue Inhibitor of Metalloproteinase-2 | 2 | 7.0 |
Tissue Inhibitor of Metalloproteinases | 2 | 3.0 |
Genes, myc | 3 | 1.0 |
France/epidemiology | 2 | 1.0 |
Growth Substances/biosynthesis | 2 | 10.0 |
Immunochemistry | 2 | 0.0 |
Genes, jun | 2 | 2.0 |
Neutralization Tests | 2 | 0.0 |
Antigens, CD/analysis | 3 | 0.0 |
Liver Cirrhosis/*metabolism | 3 | 9.0 |
Oligonucleotide Probes | 4 | 0.0 |
Alkaline Phosphatase/metabolism | 2 | 1.0 |
Gene Expression Regulation/*drug effects | 8 | 1.0 |
Evolution | 2 | 0.0 |
Endothelium, Vascular/pathology | 2 | 1.0 |
Epithelium/chemistry | 3 | 2.0 |
Molecular Probes/genetics | 2 | 2.0 |
Hepatocyte Growth Factor/metabolism/physiology | 2 | 100.0 |
Mice, Inbred CBA | 3 | 0.0 |
Transforming Growth Factor alpha/genetics/*metabolism | 2 | 13.0 |
Carcinoma, Hepatocellular/metabolism/*pathology/surgery | 2 | 100.0 |
Hyperplasia | 7 | 1.0 |
Liver Neoplasms/metabolism/*pathology/surgery | 2 | 66.0 |
Drug Therapy, Combination | 2 | 0.0 |
Liver | 3 | 5.0 |
Recombinant Proteins/biosynthesis/isolation & purification/pharmacology | 2 | 18.0 |
Gene Expression Regulation/*physiology | 2 | 0.0 |
Epithelium/drug effects/physiology | 4 | 18.0 |
Interleukin-6/*pharmacology | 2 | 0.0 |
Baculoviridae/genetics | 2 | 1.0 |
Methionine/metabolism | 3 | 2.0 |
Spodoptera | 2 | 0.0 |
Granulocyte-Macrophage Colony-Stimulating Factor/*pharmacology | 4 | 2.0 |
Insulin/pharmacology | 4 | 1.0 |
Iodine Radioisotopes/diagnostic use | 4 | 1.0 |
Luciferases/genetics | 2 | 0.0 |
Repetitive Sequences, Nucleic Acid | 2 | 0.0 |
Neoplasm Invasiveness/*physiopathology | 2 | 11.0 |
Liver/*cytology | 3 | 9.0 |
Receptor Protein-Tyrosine Kinases/physiology | 2 | 4.0 |
Lactic Acid | 2 | 3.0 |
Liver/physiopathology | 3 | 11.0 |
Growth Substances/metabolism/*pharmacology | 2 | 33.0 |
Receptors, Cell Surface/genetics/*metabolism | 2 | 1.0 |
Mesoderm/chemistry | 2 | 22.0 |
Oligodeoxyribonucleotides | 5 | 0.0 |
Receptor Protein-Tyrosine Kinases/genetics/metabolism | 2 | 3.0 |
Thyroid Gland/cytology/*drug effects/metabolism | 2 | 40.0 |
Endothelial Growth Factors/*analysis | 2 | 1.0 |
*Cell Movement | 2 | 1.0 |
Stomach Neoplasms | 3 | 9.0 |
Platelet-Derived Growth Factor/metabolism | 2 | 3.0 |
Fibronectins/biosynthesis | 3 | 20.0 |
*Protein Processing, Post-Translational | 4 | 1.0 |
*Wound Healing | 3 | 5.0 |
Menstrual Cycle | 2 | 1.0 |
RNA, Messenger/analysis/biosynthesis | 6 | 2.0 |
Recombinant Proteins/biosynthesis/pharmacology | 2 | 6.0 |
Granulocyte Colony-Stimulating Factor/*pharmacology | 2 | 1.0 |
Interleukin-3/*pharmacology | 3 | 2.0 |
Proto-Oncogene Proteins/*analysis | 3 | 1.0 |
Fibroblast Growth Factor 2/biosynthesis | 2 | 7.0 |
Transforming Growth Factor beta/*biosynthesis | 2 | 8.0 |
Liver/drug effects/*pathology | 2 | 66.0 |
Recombinant Proteins/biosynthesis | 3 | 0.0 |
*Kidney Transplantation | 2 | 0.0 |
Epithelial Cells/cytology/drug effects/metabolism | 2 | 8.0 |
Proto-Oncogene Proteins/*biosynthesis | 2 | 1.0 |
Remission Induction | 2 | 0.0 |
Neoplasm Proteins/analysis | 2 | 0.0 |
Liver/*drug effects/metabolism | 2 | 4.0 |
Polymerase Chain Reaction/methods | 4 | 0.0 |
Fibroblast Growth Factor 2/*metabolism | 2 | 3.0 |
Vascular Endothelial Growth Factor A/*metabolism | 3 | 2.0 |
Ki-67 Antigen | 2 | 0.0 |
Endothelium, Vascular/*metabolism | 2 | 0.0 |
RNA, Messenger/biosynthesis/metabolism | 2 | 4.0 |
Hepatocyte Growth Factor/blood/*therapeutic use | 2 | 100.0 |
Transgenes | 2 | 0.0 |
Plasmids/administration & dosage/genetics | 2 | 25.0 |
Insulin-Like Growth Factor I/*pharmacology | 2 | 1.0 |
Heparitin Sulfate/pharmacology | 2 | 15.0 |
Apoptosis/physiology | 3 | 0.0 |
Embryo | 5 | 1.0 |
Vascular Endothelial Growth Factor A/metabolism | 3 | 2.0 |
Aorta/cytology | 2 | 2.0 |
Tumor Markers, Biological/analysis | 2 | 0.0 |
Proto-Oncogene Protein c-kit | 3 | 3.0 |
Stem Cell Factor | 4 | 4.0 |
Bone Marrow Transplantation | 2 | 0.0 |
Chromatography, High Pressure Liquid | 2 | 0.0 |
Recombinant Proteins/biosynthesis/chemistry/pharmacology | 2 | 25.0 |
Haplorhini | 2 | 0.0 |
Hematopoietic Cell Growth Factors/*biosynthesis/genetics | 2 | 50.0 |
Hydrocortisone/pharmacology | 2 | 2.0 |
Glycosylation | 2 | 0.0 |
Receptors, Estrogen/analysis | 2 | 0.0 |
RNA, Neoplasm/genetics | 4 | 1.0 |
Gene Expression/*drug effects | 2 | 0.0 |
Skin/drug effects/*metabolism | 2 | 16.0 |
*Transcription Factors | 2 | 0.0 |
Endothelial Cells/*metabolism | 2 | 6.0 |
Protein Precursors/*metabolism | 2 | 2.0 |
Granulocyte Colony-Stimulating Factor/therapeutic use | 2 | 3.0 |
Serine Proteinase Inhibitors/pharmacology | 2 | 4.0 |
Fetus | 2 | 0.0 |
Proto-Oncogene Proteins/biosynthesis | 3 | 1.0 |
Forskolin/pharmacology | 2 | 0.0 |
Hepatocyte Growth Factor/genetics/*metabolism/*pharmacology | 2 | 100.0 |
Hematopoietic Cell Growth Factors/pharmacology | 2 | 2.0 |
Hematopoietic Stem Cells/drug effects | 3 | 5.0 |
Hepatocyte Growth Factor | 40 | 83.0 |
Fibroblast Growth Factor 1/*pharmacology | 2 | 10.0 |
Fibroblast Growth Factor 2/*pharmacology | 3 | 2.0 |
Protein Kinase C/metabolism | 5 | 1.0 |
DNA-Binding Proteins/*biosynthesis | 2 | 1.0 |
Trans-Activators/*biosynthesis | 2 | 3.0 |
Carcinoma, Squamous Cell/*metabolism/pathology | 2 | 2.0 |
DNA-Binding Proteins/genetics/metabolism | 3 | 0.0 |
Trans-Activators/genetics/metabolism | 2 | 1.0 |
Interleukin-1/*secretion | 2 | 6.0 |
Leukemia, Promyelocytic, Acute/drug therapy/*metabolism/pathology | 2 | 100.0 |
Receptor Protein-Tyrosine Kinases/*analysis/genetics | 2 | 16.0 |
Liver/enzymology | 2 | 0.0 |
Wound Healing/physiology | 3 | 5.0 |
Hepatocyte Growth Factor/chemistry/*physiology | 3 | 100.0 |
Exons | 5 | 0.0 |
Introns | 4 | 0.0 |
Genes, Immediate-Early | 2 | 3.0 |
Proto-Oncogene Proteins/*genetics | 3 | 0.0 |
Clone Cells/cytology | 2 | 10.0 |
Liver/cytology/drug effects/metabolism | 2 | 16.0 |
Heparan Sulfate Proteoglycan | 2 | 6.0 |
Transforming Growth Factor alpha/analysis | 2 | 6.0 |
Chromatography, Ion Exchange | 3 | 0.0 |
Carcinoma/metabolism | 2 | 3.0 |
Chromatography, Gel | 2 | 0.0 |
Liver/drug effects/metabolism | 2 | 2.0 |
Recombinant Proteins/metabolism/pharmacology | 3 | 2.0 |
Substrate Specificity | 4 | 0.0 |
DNA/*biosynthesis/drug effects | 2 | 20.0 |
Drug Interactions | 3 | 0.0 |
1-Methyl-3-isobutylxanthine/pharmacology | 2 | 2.0 |
Cyclic AMP/*metabolism | 2 | 0.0 |
Skin/*metabolism | 2 | 1.0 |
Heparitin Sulfate/metabolism | 2 | 5.0 |
Chromosomes, Human, Pair 7 | 3 | 1.0 |
Breast Neoplasms/metabolism | 2 | 1.0 |
DNA | 3 | 0.0 |
Hepatocyte Growth Factor/*biosynthesis/genetics/pharmacology | 2 | 100.0 |
Moths | 2 | 4.0 |
Lung/embryology | 2 | 10.0 |
*Regeneration | 4 | 14.0 |
Plasmids/genetics | 2 | 0.0 |
Hepatocyte Growth Factor/*antagonists & inhibitors/genetics | 2 | 100.0 |
Receptors, Fibroblast Growth Factor/genetics/metabolism | 2 | 8.0 |
Poly A/genetics | 2 | 4.0 |
Colonic Neoplasms/genetics/*pathology | 2 | 13.0 |
Cross Reactions | 2 | 0.0 |
Chromosome Banding | 3 | 0.0 |
Protein-Tyrosine Kinase/*analysis | 2 | 6.0 |
Receptors, Cell Surface/*physiology | 2 | 0.0 |
Colony-Stimulating Factors/*therapeutic use | 2 | 40.0 |
Filgrastim | 2 | 20.0 |
Hematopoietic Stem Cells/*drug effects | 2 | 3.0 |
Matrix Metalloproteinases/metabolism | 2 | 4.0 |
NIH 3T3 Cells | 3 | 1.0 |
Antibodies | 2 | 0.0 |
Lung Neoplasms/*genetics | 2 | 0.0 |
Sulfur Radioisotopes | 2 | 2.0 |
Dexamethasone/*pharmacology | 2 | 0.0 |
Keratinocytes/*physiology | 2 | 5.0 |
RNA/genetics/isolation & purification | 2 | 1.0 |
Hematopoietic Stem Cell Transplantation/methods | 2 | 11.0 |
Vascular Endothelial Growth Factor A/*blood | 4 | 3.0 |
Cytokines/*genetics | 2 | 1.0 |
Growth Substances/*genetics | 10 | 9.0 |
Receptors, Cell Surface/physiology | 3 | 2.0 |
Tissue Inhibitor of Metalloproteinase-1/metabolism | 2 | 7.0 |
Growth Substances/*genetics/isolation & purification/pharmacology | 2 | 66.0 |
Adrenal Glands/metabolism | 2 | 4.0 |
Stomach/metabolism | 2 | 5.0 |
DNA Replication/*drug effects | 2 | 3.0 |
Recombinant Proteins/isolation & purification/pharmacology | 2 | 13.0 |
Growth Substances/*genetics/isolation & purification | 2 | 66.0 |
Genetic Markers | 2 | 0.0 |
Electrophoretic Mobility Shift Assay | 2 | 0.0 |
Liver/drug effects | 2 | 5.0 |
Sendai virus/*genetics | 2 | 50.0 |
Endothelium, Vascular/*cytology/metabolism | 2 | 3.0 |
Macrophages/physiology | 2 | 2.0 |
Monocytes/physiology | 2 | 1.0 |
Nitric-Oxide Synthase/*metabolism | 3 | 3.0 |
Cluster Analysis | 2 | 1.0 |
Pancreatic Neoplasms/*enzymology/*pathology | 2 | 40.0 |
Urinary Plasminogen Activator/*metabolism | 2 | 5.0 |
Colony-Stimulating Factors/*genetics | 2 | 28.0 |
Interleukins/*genetics | 3 | 10.0 |
Periodontitis/metabolism | 2 | 33.0 |
Blood Platelets/metabolism | 2 | 1.0 |
RNA, Messenger/*genetics | 2 | 0.0 |
*Genes, Structural | 2 | 0.0 |
Models, Genetic | 3 | 0.0 |
Adenoviridae/genetics | 4 | 0.0 |
Islets of Langerhans Transplantation/*methods | 2 | 66.0 |
Interleukin-6 | 9 | 20.0 |
Internet | 2 | 2.0 |
Random Allocation | 3 | 0.0 |
Epithelial Cells/*cytology | 2 | 8.0 |
Interferon Type I/*genetics | 2 | 11.0 |
Proteins/*genetics | 2 | 0.0 |
Fibroblast Growth Factors/physiology | 2 | 11.0 |
Multiple Myeloma/blood/*diagnosis/mortality | 2 | 100.0 |
Hepatocyte Growth Factor/secretion | 2 | 100.0 |
Interleukin-8/secretion | 2 | 5.0 |
Enzyme Inhibitors/metabolism | 3 | 1.0 |
Luminescent Proteins/genetics | 2 | 1.0 |
Prostatic Neoplasms/*metabolism | 2 | 1.0 |
Collagen Type I/metabolism | 2 | 5.0 |
Fibroblasts/cytology/*metabolism | 2 | 5.0 |
Dependovirus/genetics | 2 | 6.0 |
Embryo Implantation/*physiology | 2 | 5.0 |
Heparin/administration & dosage | 2 | 8.0 |
Carcinoma, Papillary/*metabolism | 3 | 25.0 |
Thyroid Neoplasms/*metabolism | 3 | 7.0 |
Intercellular Signaling Peptides and Proteins/physiology | 2 | 11.0 |
Hepatocyte Growth Factor/*blood/secretion | 2 | 100.0 |
Tumor Cells, Cultured/drug effects/pathology | 2 | 4.0 |
Epithelial Cells/cytology/enzymology | 2 | 18.0 |
Injections, Intraperitoneal | 2 | 1.0 |
Keratinocytes/metabolism | 2 | 1.0 |
Recombinant Proteins/*pharmacology | 2 | 2.0 |
Collagen Type I/*metabolism | 2 | 33.0 |
Intercellular Signaling Peptides and Proteins/*blood | 2 | 3.0 |
Bone Marrow Cells/*drug effects/metabolism | 2 | 40.0 |
Stromal Cells/*drug effects/metabolism | 2 | 40.0 |
Insulin/metabolism | 2 | 1.0 |
Interleukin-6/*metabolism | 2 | 1.0 |
